documents incorporated reference table c parts ii portions registrant 's annual report shareholders iii fiscal year annual report parts iii portions registrant 's proxy statement annual meeting proxy statement table part table caption item c c business general segments business consumer pharmaceutical medical devices diagnostics geographic areas raw materials patents trademarks seasonality competition research environment regulation available information properties legal proceedings submission matters vote security holders executive officers registrant part ii market registrant 's common equity related stockholder matters issuer purchases equity securities selected financial data management 's discussion analysis results operations financial condition quantitative qualitative disclosures marketrisk financial statements supplementary data changes disagreements accounting financial disclosure controls procedures part iii directors executive officers registrant executive compensation security ownership certain beneficial owners management certain relationships related transactions principal accountant fees services part iv exhibits financial statement schedules signatures report independent registered public accounting firm financial statement schedule exhibit index table part item business general johnson johnson employing approximately people worldwide engaged manufacture sale broad range products health care field johnson johnson subsidiaries conduct business virtually countries world johnson johnson 's primary interest historically currently products related human health wellbeing johnson johnson organized state new jersey johnson johnson organized principle decentralized management executive committee johnson johnson principal management group responsible operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices diagnostics business segments subsidiary within business segments exceptions managed citizens country located segments business johnson johnson 's worldwide business divided three segments consumer pharmaceutical medical devices diagnostics additional information required item incorporated herein reference narrative tabular graphic descriptions segments operating results management 's discussion analysis results operations financial condition pages johnson johnson 's annual report shareholders fiscal year filed exhibit report consumer consumer segment manufactures markets broad range products used baby child care skin care oral wound care women 's health care fields well overthecounter pharmaceutical nutritional products major brands include aveeno skin care products bandaid brand adhesive bandages carefree pantiliners clean clear teen skin care products johnson 's baby line products motrin ib ibuprofen products pepcid ac acid controller johnson johnson merck consumer pharmaceuticals co neutrogena skin hair care products roc skin care products splenda calorie sweetener stayfree sanitary protection products broad family tylenol acetaminophen products products marketed principally general public sold wholesalers directly independent chain retail outlets throughout world pharmaceutical pharmaceutical segment 's principal worldwide franchises antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology fields products distributed directly wholesalers health care professionals use prescription general public key products pharmaceutical segment include procrit epoetin alfa sold outside us eprex biotechnology derived product stimulates red blood cell production duragesic fentanyl transdermal system sold abroad durogesic atreatment chronic pain offers novel delivery system risperdal risperidone risperdal consta risperidone longacting injection treatment symptoms schizophrenia remicade infliximab novel monoclonal antibody therapy indicated treat symptoms crohn 's disease rheumatoid arthritis ankylosing spondylitis levaquin levofloxacin floxin ofloxacin antiinfective field topamax topiramate antiepileptic migraine prevention treatment ortho evra norelgestrominethinyl estradiol transdermal system first contraceptive patch approved food drug administration fda ortho tricyclen lo norgestimateethinyl estradiol low dose oral contraceptive doxil doxorubicin cancer treatment ditropan xl oxybutynin chloride treatment overactive bladder reminyl galantamine hbr patients mild moderate alzheimer 's disease natrecor nesiritide novel agent approved congestive heart failure velcade bortezomib oncology treatment concerta methylphenidate hcl product treatment attention deficit hyperactivity disorder medical devices diagnostics medical devices diagnostics segment includes broad range products used direction physicians nurses therapists hospitals diagnostic laboratories clinics products include ethicon 's wound care women 's health products ethicon endosurgery 's minimally invasive surgical products cordis ' circulatory disease management products lifescan 's blood glucose monitoring products orthoclinical diagnostics ' professional diagnostic products depuy 's orthopaedic joint reconstruction spinal sports medicine products vistakon 's disposable contact lenses distribution health care professional markets done directly surgical supply dealers geographic areas international business johnson johnson conducted subsidiaries located countries outside united states selling products virtually countries throughout world products made sold international business include many described business consumer pharmaceutical medical devices diagnostics however principal markets products methods distribution international business vary country culture products sold international business include developed united states also developed subsidiaries abroad investments activities countries outside united states subject higher risks comparable us activities investment commercial climate influenced restrictive economic policies political uncertainties raw materials raw materials essential johnson johnson 's operating companies ' businesses generally readily available multiple sources patents trademarks johnson johnson made practice obtaining patent protection products processes possible johnson johnson owns licensed number patents relating products manufacturing processes aggregate believed material importance operation business sales company 's two largest products procrit risperdal accounted johnson johnson 's total revenues accordingly patents related products believed material relation johnson johnson whole duragesic fentanyl transdermal system united states eprex international markets lost lose basic patent protection subject generic competition pediatric exclusivity duragesic patent expired us january first generic version duragesic launched foreign patent protection related duragesic expire company expects duragesic sales decline compared patents related eprex certain international markets expired generic competition limited near term due lack biologically equivalent compounds sales duragesic eprex accounted johnson johnson 's worldwide sales major product patents scheduled expire next years johnson johnson made practice selling products undertrademarks obtaining protection trademarks available means johnson johnson 's trademarks protected registration united states countries products marketed johnson johnson considers trademarks aggregate material importance operation business seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research grants competition product lines johnson johnson companies compete companies large small located united states abroad competition strong lines without regard number size competing companies involved competition research involving development new products processes improvement existing products processes particularly significant results time time product process obsolescence development new improved products important johnson johnson 's success areas business competitive environment requires substantial investments continuing research multiple sales forces addition winning retention customer acceptance products johnson johnson 's consumer businesses involve heavy expenditures advertising promotion selling research research activities important segments johnson johnson 's business major research facilities located united states also australia belgium brazil canada united kingdom costs johnson johnson 's worldwide research activities relating development new products improvement existing products technical support products compliance governmental regulations protection consumer amounted million fiscal years respectively costs charged directly income year incurred research sponsored johnson johnson environment past year johnson johnson companies subject variety federal state local environmental protection measures johnson johnson believes operations comply material respects applicable environmental laws regulations johnson johnson 's compliance requirements expected material effect upon capital expenditures cash flows earnings competitive position regulation johnson johnson 's business subject varying degrees governmental regulation countries operations conducted general trend toward regulation increasing stringency united states drug device diagnostics cosmetic industries long subject regulation various federal state local agencies primarily product safety efficacy advertising labeling exercise broad regulatory powers food drug administration fda continues result increases amounts testing documentation required fda clearance new drugs devices corresponding increase expense product introduction similar trends toward product process regulation also evident number major countries outside united states especially european economic community efforts continuing harmonize internal regulatory systems costs human health care continue subject study investigation regulation governmental agencies legislative bodies united states countries united states attention focused drug prices profits programs encourage doctors write prescriptions particular drugs recommend particular medical devices managed care become potent force market place likely increased attention paid drug medical device pricing appropriate drug medical device utilization quality health care also uncertainty impact medicare prescription drug improvement modernization act enacted latter part regulatory agencies whose purview johnson johnson operates administrative powers may subject johnson johnson actions product recalls seizure products civil criminal sanctions cases johnson johnson may deem advisable initiate product recalls voluntarily addition sales marketing business practices health care industry come increased scrutiny government agencies state attorney generals resulting investigations prosecutions carry risk significant civil criminal penalties company 's affiliates sell cox inhibitor medicines recent developments involving medicines vioxx celebrex likely implications throughout health care industry available information copies johnson johnson 's quarterly reports form q annual report current reports form k amendments foregoing provided without charge shareholder submitting written request secretary principal executive offices company calling company 's securities exchange commission sec filings also available company 's web site wwwinvestorjnjcomgovernance soon reasonably practicable electronically filed furnished sec sec filings also available sec web site wwwsecgov addition charters audit committee compensation benefits committee nominating corporate governance committee board directors company 's principles corporate governance policy business conduct code business conduct ethics directors executive officers available wwwinvestorjnjcomgovernance web site address provided without charge shareholder submitting written request provided item properties johnson johnson worldwide subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments johnson johnson 's business approximately follows table caption square feet segment thousands c consumer pharmaceutical medical devices diagnostics worldwide total table within united states facilities used consumer segment pharmaceutical segment medical devices diagnostics segment johnson johnson 's manufacturing operations outside united states often conducted facilities serve one segment business locations manufacturing facilities major geographic areas world follows table caption number square feet geographic area facilities thousands c c united states europe western hemisphere excluding usa africa asia pacific worldwide total table addition manufacturing facilities discussed johnson johnson maintains numerous office warehouse facilities throughout world research facilities also discussed item business research johnson johnson generally seeks manufacturing facilities although principally locations abroad leased office warehouse facilities often leased johnson johnson 's properties maintained good operating condition repair well utilized information regarding lease obligations see note rental expense lease commitments notes consolidated financial statements annual report filed exhibit report segment information additions property plant equipment contained annual report filed exhibit report item legal proceedings information set forth note legal proceedings notes consolidated financial statements pages annual report incorporated herein reference filed exhibit report company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state laws primary relief sought cost past future remediation feasible predict determine outcome proceedings opinion company proceedings would material adverse effect results operations cash flows financial position company item submission matters vote security holders applicable executive officers registrant listed executive officers johnson johnson march unless otherwise indicated employee company affiliates held position indicated past five years family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal information regard directors company including following executive officers directors incorporated herein reference pages johnson johnson 's proxy statement dated march proxy statement table caption name age position c c robert j darretta vice chairman board directors member executive committee chief financial officer russell c deyo member executive committee vice president general counsel chief compliance officera michael j dormer member executive committee worldwide chairman medical devicesb kaye fostercheek member executive committee vice president human resourcesc colleen goggins member executive committee worldwide chairman consumer personal care groupd joann heffernan heisen member executive committee vice president chief information officereper peterson md phd member executive committee chairman pharmaceuticals research developmentf christine poon vice chairman member executive committee worldwide chairman medicines nutritionals joseph c scodari member executive committee worldwide chairman pharmaceuticals groupg nicholas j valeriani member executive committee worldwide chairman cardiovascular devices diagnosticsh william c weldon chairman board directors chief executive officer chairman executive committee table mr r c deyo joined company became associate general counsel became member executive committee vice president administration vice president general counsel chief compliance officer april b mr j dormer joined company company group chairman worldwide franchise chairman depuy codman company acquired depuy inc time acquisition chief operating officer depuy inc since mr dormer became member executive committee franchise group chairman medical devices april mr dormer named worldwide chairman medical devices group c ms k fostercheek joined company vice president human resources johnson johnson consumer products companies march named vice president human resources consumer personal care group named member human resources leadership team consumer personal care group operating committee ms fostercheek became member executive committee vice president human resources company january prior joining company ms fostercheek served various human resources management positions pfizer years recently supporting pharmaceutical business japan asia africa middle east latin america ms c goggins joined company held various positions becoming president personal products company named president johnson johnson consumer products company company group chairman north america johnson johnson consumer products ms goggins became member executive committee worldwide chairman consumer personal care group e ms j h heisen joined company became treasurer controller became member executive committee vice president chief information officer f dr p peterson joined company vice president drug discovery rw johnson pharmaceutical research institute named group vice president pharmaceutical research institute april president november dr peterson named chairman pharmaceuticals research development dr peterson became member executive committee g mr j c scodari joined company president centocor company acquired centocor time acquisition president chief operating officer centocor member centocor 's board directors since december march named company group chairman north american pharmaceutical business became member pharmaceuticals group operating committee march mr scodari named company group chairman biopharmaceutical businesses mr scodari named worldwide chairman pharmaceuticals group became member executive committee march h mr n j valeriani joined company held various positions becoming president ethicon endosurgery inc january named company group chairman ethicon endosurgery additional responsibility johnson johnson medical products medical devices diagnostics business canada became worldwide franchise chairman depuy franchise mr valeriani became member executive committee vice president human resources september february assumed additional responsibilities worldwide chairman diagnostics january mr valeriani appointed worldwide chairman cardiovascular devices diagnostics relinquishedhis human resources responsibilities part ii item market registrant 's common equity related stockholder matters issuer purchases equity securities march approximately record holders common stock company information called item incorporated herein reference material captioned management 's discussion analysis results operations financial condition share repurchase dividends common stock market prices note notes consolidated financial statements pages annual report filed exhibit report equity compensation plan information pages proxy statement following table provides information respect common stock share purchases company fiscal stock purchases made part systematic plan meet company 's compensation programs table caption total number shares average price paid fiscal month purchased per share c c december january january february february march march april april may may june june july july august august september september october october november november january table item selected financial data information called item incorporated herein reference material captioned summary operations statistical data annual report filed exhibit report form k item management 's discussion analysis results operations financial condition information called item incorporated herein reference narrative tabular graphic material included material captioned management 's discussion analysis results operations financial condition pages annual report filed exhibit report item quantitative qualitative disclosures market risk information called item incorporated herein reference material captioned management 's discussion analysis results operations financial condition liquidity capital resources pages annual report filed exhibit report form k item financial statements supplementary data information called item incorporated herein reference audited consolidated financial statements notes thereto material captioned report independent registered public accounting firm pages annual report filed exhibit report item changes disagreements accountants accounting financial disclosure applicableitem controls procedures disclosure controls end fiscal fourth quarter company evaluated effectiveness design operation disclosure controls procedures company 's disclosure controls procedures designed ensure company records processes summarizes reports timely manner information company must disclose reports filed securities exchange act william c weldon chairman chief executive officer robert j darretta vice chairman chief financial officer reviewed participated evaluation based evaluation messrs weldon darretta concluded date evaluation company 's disclosure controls procedures effective internal control management 's report internal control financial reporting included report item fiscal quarter ended january significant changes company 's internal control financial reporting materially affected reasonably likely materially affect company 's internal control financial reporting management 's report internal control financial reporting section sarbanesoxley act management required assess effectiveness company 's internal control financial reporting end fiscal year report based assessment whether company 's internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting company 's internal control financial reporting designed provide reasonable assurance reliability company 's financial reporting preparation financial statements external purposes accordance generally accepted accounting principles internal control financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate company 's management assessed effectiveness company 's internal control financial reporting january making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring company 's assessment included extensive documenting evaluating testing design operating effectiveness internal control financial reporting based company 's processes assessment described management concluded january company 's internal control financial reporting effective management 's assessment effectiveness company 's internal control financial reporting january audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears report independent registered public accounting firm annual report incorporated herein reference part iii item directors executive officers registrant information called item incorporated herein reference material caption election directors nominees pages proxy statement b material part hereof caption executive officers registrant c discussion audit committee heading directors ' fees committees meetings pages proxy statement material caption section beneficial ownership reporting compliance proxy statement company 's policy business conduct covers employeesincluding chief executive officer chief financial officer controller meets requirements sec rules promulgated section sarbanesoxley act policy business conduct available company 's web site wwwjnjcom copies policy business conduct available shareholders without charge upon written request secretary company 's principal address substantive amendment policy business conduct waiver policy granted chief executive officer chief financial officer controller also posted company 's web site wwwjnjcom within five business days retained web site least one year addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics directors executive officers available company 's web site wwwjnjcom copies code business conduct ethics available shareholders without charge upon written request secretary company 's principal address substantive amendment code waiver code granted member board directors executive officer also posted company 's web site wwwjnjcom within five business days retained web site least one year item executive compensation information called item incorporated herein reference following sections proxy statement election directors directors ' fees committees meetings pages compensation benefits committee report executive compensation pages shareholder return performance graphs pages executive compensation pages item security ownership certain beneficial owners management information called item incorporated herein reference material captioned election directors stock ownershipcontrol proxy statement note notes consolidated financial statements pages annual report filed exhibit report item certain relationships related transactions applicable item principal accountant fees services information called item incorporated herein reference material headings appointment independent auditors preapproval audit nonaudit services pages proxy statement part iv item exhibits financial statement schedules following documents filed part report financial statements following audited consolidated financial statements notes thereto report independent registered public accounting firm pages annual report incorporated herein reference filed exhibit report consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements report independent registered public accounting firm financial statement schedulesschedule ii valuation qualifying accounts schedules listed omitted required applicable exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report johnson johnson subsidiaries schedule ii valuation qualifying accounts fiscal years ended january december december dollars millions table caption balance balance beginning payments end period accruals period c c c c accrued rebates returns promotions reserve doubtful accounts reserve cash discounts accrued rebates returns promotions reserve doubtful accounts reserve cash discounts accrued rebates returns promotions reserve doubtful accounts reserve cash discounts table includes reserve customer rebates january december december respectively includes related reversal previously estimated performancebased rebate allowances managed care contracts certain prior year amounts reclassified conform current year presentation signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized date march johnson johnson registrant w c weldon w c weldon chairman board directors chief executive officer pursuant requirements securities exchange act thisreport signed following persons behalf registrant capacities dates indicated table caption signature title date c c w c weldon chairman board directors march chief executive officer w c weldon director principal executive officer r j darretta vice chairman board directors march chief financial officer director r j darretta principal financial officer j cosgrove controller march j cosgrove g n burrow director march g n burrow coleman director march coleman j g cullen director march j g cullen j folkman director march j folkman jordan director march jordan g langbo director march g langbo table table caption signature title date c c l lindquist director march l lindquist lf mullin director march lf mullin reinemund director march reinemund satcher director march satcher h b schacht director march h b schacht table report independent registered public accounting firm financial statement schedule shareholders board directors johnson johnson audits consolidated financial statements management 's assessment effectiveness internal control financial reporting effectiveness internal control financial reporting referred report dated february appearing annual report shareholders johnson johnson report consolidated financial statements assessment incorporated reference annual report also included audit financial statement schedule listed item opinion financial statement schedule presents fairly material respects information set forth therein read conjunction related consolidated financial statements pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york march exhibit index table caption reg sk exhibit table description item exhibit c ai restated certificate incorporation dated april incorporated herein reference exhibit registrant 's annual report year ended december aii certificate amendment restated certificate incorporation company dated may incorporated herein reference exhibit registrant 's annual report year ended january aiii certificate amendment restated certificate incorporation company dated may incorporated herein reference exhibit aiii registrant 's form k annual report year ended december aiv certificate amendment restated certificate incorporation company effective may incorporated herein reference exhibit registrant 's form q quarterly report quarter ended july b bylaws company amended effective june incorporated herein reference exhibit registrant 's form q quarterly report quarter ended july upon request securities exchange commission registrant furnish copy instruments defining rights holders long term debt registrant stock option plan nonemployee directors incorporated herein reference exhibit registrant 's annual report year ended december b stock option plan amended incorporated herein reference exhibit b registrant 's annual report year ended december c stock option plan amended incorporated herein reference exhibit b registrant 's annual report year ended january stock option plan amended incorporated herein reference exhibit c registrant 's annual report year ended december e stock compensation plan incorporated herein reference exhibit e registrant 's annual report year ended december f executive incentive plan amended incorporated herein reference exhibit f registrant 's annual report year ended december g domestic deferred compensation certificate extra compensation plan amended incorporated herein reference exhibit g registrant 's annual report year endeddecember h deferred fee plan nonemployee directors amended filed document executive income deferral plan amended incorporated herein reference exhibit registrant 's annual report year ended december j excess savings plan incorporated herein reference exhibit j registrant 's annual report year ended december k supplemental retirement plan incorporated herein reference exhibit h registrant 's annual report year ended january l executive life insurance plan incorporated herein reference exhibit registrant 's annual report year ended january table table caption reg sk exhibit table description item exhibit c stock option gain deferral plan incorporated herein reference exhibit registrant 's annual report year ended january n estate preservation plan incorporated herein reference exhibit n registrant 's annual report year ended january letter agreement dated june company mr r larsen respect postemployment arrangements incorporated herein reference exhibit registrant 's annual report year ended december p consulting agreement company dr judah folkman member board incorporated herein reference exhibit p registrant 's annual report year ended december q summary compensation arrangements named executive officers directors filed document statement computation ratio earnings fixed charges filed document pages company 's annual report shareholders fiscal year portions annual report incorporated reference report deemed filed filed document subsidiaries filed document consent independent registered public accounting firm filed document certification chief executive officer pursuant section sarbanesoxley act filed document b certification chief financial officer pursuant section sarbanesoxley act filed document certification chief executive officer pursuant section sarbanesoxley act furnished document b certification chief financial officer pursuant section sarbanesoxley act furnished document b cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements filed document table management contracts compensatory plans arrangements required filed exhibits form pursuant item report form k copy exhibits listed provided without charge shareholder submitting written request specifying desired exhibits secretary principal executive offices company text document document typeexhsequence filenameyexvwhtxt descriptiondeferred fee plan directors amended text exhibit h johnson johnson deferred fee plan directors amended february purpose purpose johnson johnson deferred fee plan directors plan provide outside directors johnson johnson company opportunity defer receipt compensation earned director date following termination service provision opportunity designed aid company attracting retaining members board directors persons whose abilities experience judgment contribute well company effective date original effective date plan january plan amended entirety effective january december eligibility director company also employee company related company shall eligible participate plan deferred compensation account deferred compensation account shall established director amount deferral participant effective retroactive january may elect defer receipt specified part cash compensation payable participant serving board directors serving committees board directors company amount equal deferred compensation credited participant 's deferred compensation account quarterly basis dividend payment date quarter payment date event shall dividend payment date quarter payment date shall deemed last business day quarter deferred compensation account hypothetical investment options unless otherwise specified participant pursuant terms paragraph b section amounts elected deferred plan calendar year deferrals shall credited participant 's deferred compensation account converted equivalent units johnson johnson common stock company stock adjusted compensation deferred invested company stock payment date date final payment pursuant section hereof company stock equivalent units number company stock equivalent units shall determined dividing amount compensation payable average high low price company stock traded new york stock exchange trading day immediately prior payment date reported bloomberg another financial reporting service selected company sole discretion number company stock equivalent units included participant 's deferred compensation account shall adjusted reflect dividends value account shall adjusted reflect increases decreases market value would resulted funds equal balance participant 's deferred compensation account invested company stock nothing herein obligates company purchase company stock company stock purchased shall remain sole property company b election participant made provided section deferred compensation account credited interest payment date date final payment pursuant section hereof rate equal annual rate growth investment johnson johnson certificate extra compensation plan cec plan prior year provided however computation said growth rate shall include dividend equivalents paid cec plan election permitted section b shall available participant becomes participant plan december c respect company stock equivalent units deferred compensation account company shall credit account dividend payment date declared respect company 's stock number company stock equivalent units equal product dividend per shareof company 's stock payable dividend payment date multiplied z number company stock equivalent units credited account applicable dividend record date divided ii average high low price company stock traded new york stock exchange trading day immediately prior dividend payment date reported bloomberg another financial reporting service selected company sole discretion fractional company stock equivalent units shall carried forward fractional dividend equivalent units shall payable thereon account balances company stock equivalent units company 's retirement plan nonemployee directors transferred hisher deferred compensation account plan january reason termination retirement plan shall treated purposes plan deferrals time election deferral participant may change amount compensation deferred andor ii option elected section respect hisher account deferrals subsequent years annually december completing forms provided company purpose change shall become effective january following year participant elects change hisher investment option available section participant 's account shall valued december value entered hisher account new investment option following january except change company stock equivalent units first trading day following january shall used value deferred compensation account value participant 's deferred compensation account shall case may include compensation deferred interest credited thereon adjustments dividends increases decreases market value company stock pursuant option selected section otherwise required plan company stock trade date calculation common stock equivalent units made plan next preceding date stock traded shall utilized payment deferred compensation upon participant 's completion service member board directors completion date participant event participant 's death named beneficiary hisher estate shall entitled receive cash lump sum value hisher deferred compensation account completion date unless participant elected pursuant provisions section defer payment hisher deferred compensation account beyond completion date company stock equivalent units shall valued average high low price company 's stock traded new york stock exchange trading day immediately prior date reported bloomberg another financial reporting service selected company sole discretion withdrawal may made participant 's deferred compensation account prior completion date value participant 's deferred compensation account shall subject election made pursuant section paid soon practicable following completion date death deferral election addition deferral elections referred participant may also elect manner provided continue defer receipt hisher deferred compensation account beyond hisher completion date value participant 's account hisher completion date may deferred taxable years following completion date installments elected first installment payment may made immediately completion date deferred taxable years installment payments made annually manner described approximately equal amounts ie balance account minimum number installments two maximum number provided however payments shall made within ten years completion date participant may elect defer value hisher account completion date percentage increment less deferred installment payments shall made cash following additional rules shall apply immediate lump sum payment participant receive full value hisher account calendar month hisher completion date b deferred lump sum payment participant receive full value hisher account january year heshe elects receive payment c immediate commencement installments participant receive first installment calendar month hisher completion date allsubsequent installments january year deferred commencement installments participant receive first subsequent installments january year e event death participant company make payment full balance account soon administratively practical single lump sum payment designated beneficiary hisher estate f making payment due january value participant 's account first trading day month shall utilized deferrals following completion date shall invested company stock equivalent units described section extent participant 's account credited annual growth rate investment cec plan described section b account shall converted common stock equivalent units completion date election participant defer payment elect installments part hisher deferred compensation account beyond completion date must made minimum twelve months prior completion date election may revised revoked twelve months prior completion date time election may revoked otherwise revised notwithstanding upon implementation plan exception made participants completion date participants deferral installment election must made minimum three months calendar year prior completion date example participant completion date april must make deferral andor installment election later december election defer andor receive installment payments may revised revoked prior last permissible date making election time election may revoked otherwise revised election defer payment andor paid installments beyond completion date effective filed extra compensation services form utilized purposes election made required deadline shall disregarded designation beneficiary participant may time time writing filed secretary company designate legal natural person persons may designated contingently successively payments participant 's deferred compensation account made participant dies prior receipt payment account beneficiary designation effective signed form filed secretary company participant alive cancel beneficiary designation forms filed earlier participant fails designate beneficiary provided designated beneficiaries die participant complete payment deferred compensation account account shall paid estate last die participant designated beneficiaries soon practicable death participant 's rights unsecured right participant receive payment provisions plan shall unsecured claim general assets company provisions contained plan shall construed give participant beneficiary time security interest deferred compensation account asset trust company benefit participant beneficiary statement account statement sent participants soon practical following end year value hisher deferred compensation account december year assignability right receive payments hereunder shall transferable assignable participant beneficiary except laws descent distribution administration plan plan shall administered committee appointed responsible board directors committee shall consist less three directors company committee shall act vote written consent majority members amendment termination plan plan may time time time amended modified terminated compensation committee board directors board directors company amendment modification termination shall without consent participant adversely affect participant 's accruals deferred compensation accounts governing law agreement shall governed construed accordance laws state new jersey text document document typeexq sequence filenameyexvwqtxt descriptionsummary compensation text exhibit q summary compensation arrangements named executive officers directors compensation arrangements named executive officers following description compensation arrangements approved compensation benefits committee compensation committee february company 's chief executive officer four highly compensated executive officers named executive officers compensation committee approved following base salaries effective march named executive officers table c william c weldon chairmanceo robert j darretta vice chairmancfo chris poon vice chairmanworldwide chairman medicines nutritionals group per peterson chairman rd pharmaceuticals group russell c deyo vice president general counsel table compensation committee approved following bonus payments performance comprised cash fair market value common stock awards february table c mr weldon mr darretta ms poon dr peterson mr deyo table compensation committee approved following stock option grants company 's stock option plan exercise price fair market value company 's common stock date grant options become exercisable february expire february table c mr weldon mr darretta ms poon dr peterson mr deyo table compensation committee approved following long term incentive plan awards recognition performance company 's certificate extra compensation cec program awards paid retirement termination employment end fiscal year cec value per unit value cec units subject increase decrease based performance companytable c mr weldon cec units mr darretta cec units ms poon cec units dr peterson cec units mr deyo cec units table compensation arrangements nonemployee directors nonemployee director receives annual fee services director addition directors receive service committee board directors chairperson committee presiding director paid annual fee longterm incentive plan submitted shareholders approval annual meeting nonemployee director would receive nonretainer equity compensation year form restricted deferred stock value subject shareholder approval longterm incentive plan nonemployee director receive grant shares restricted stock based upon fair market value common stock company february shares restricted stock issued unless plan approved shareholders addition future director receive onetime grant shares company common stock upon first becoming member board directors text document document typeex sequence filenameyexvtxt descriptionstatement computation ratio earnings text exhibit johnson johnson subsidiaries statement computation ratio earnings fixed charges dollars millions table caption fiscal year ended january december december december december c c c c c determination earnings earnings provision taxes income fixed charges total earnings defined fixed charges rents interest expense capitalization interest total fixed charges ratio earnings fixed charges table ratio earnings fixed charges computed dividing sum earnings provision taxes income fixed charges fixed charges fixed charges represent interest expense interest capitalized amortization debt discount appropriate interest factor operating leases textdocument document typeex sequence filenameyexvtxt descriptionpages annual report shareholders text exhibit management 's discussion analysis results operations financial condition organization business segments description company business segments company subsidiaries approximately employees worldwide engaged manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices diagnostics consumer segment manufactures markets broad range products used baby child care skin care oral wound care women 's health care fields well nutritional overthecounter pharmaceutical products products marketed principally general public sold wholesalers directly independent chain retail outlets throughout world pharmaceutical segment includes products following therapeutic areas antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology areas products distributed directly retailers wholesalers health care professionals prescription use general public medical devices diagnostics segment includes broad range products used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics products include circulatory disease management products depuy 's orthopaedic joint reconstruction spinal care products ethicon 's wound care women 's health products ethicon endosurgery 's minimally invasive surgical products lifescan 's blood glucose monitoring products orthoclinical diagnostics ' professional diagnostic products vision care 's disposable contact lenses company 's structure based upon principle decentralized management executive committee johnson johnson principal management group responsible operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices diagnostics business segments subsidiary within business segments exceptions managed citizens country located product lines company competes companies large small located throughout world competition strong product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new improved products important company 's success areas business competitive environment requires substantial investments continuing research multiple sales forces addition development maintenance customer acceptance company 's consumer products involves significant expenditures advertising promotion management 's objectives company 's objective achieve superior levels capital efficient profitable growth accomplish company 's management operates business consistent certain strategic principles proven successful time end company participates growth areas human health care committed attaining leadership positions growth segments development innovative products services new products introduced within past five years accounted sales billion sales invested research development recognizing importance ongoing development new differentiated products services sustain long term growth operating companies located countries companyviews principle decentralized management asset fundamental success broadly based business also fosters entrepreneurial spirit combining extensive resources large organization ability react quickly local market changes challenges company committed developing global business leaders drive growth objectives businesses managed long term order sustain leadership positions achieve growth provides enduring source value shareholders unifying management team company 's dedicated employees achieving objectives johnson johnson credo credo provides common set values serves constant reminder company 's responsibilities customers employees communities shareholders company believes basic principles along overall mission improving quality life people everywhere enable johnson johnson continue among leaders health care industry results operations analysis consolidated sales worldwide sales increased billion compared increases sales increases consist following table caption sales increase due c c c volume price currency total table sales us companies billion billion billion represents increase sales international companies billion billion billion represents increase graph last five years annual compound growth rates worldwide us international sales respectively tenyear annual compound growth rates worldwide us international sales respectively graph international geographic areas experienced doubledigit sales growth consisting europe western hemisphere excluding us asiapacific africa regions sales gains include positive impact currency fluctuations us dollar foreign currencies europe western hemisphere excluding us asiapacific africa region sales three largest distributors cardinal distribution mckesson hboc amerisourcebergen corp accounted respectively total revenues sales distributors accounted respectively total revenues results benefited inclusion rd week see note annual closing date details company estimated fourth quarter growth rate enhanced approximately year approximately additional week added sales also brought full week 's worth operating costs therefore net earnings impact negligible graph analysis sales business segments consumer segment consumer segment sales billion increase operational growth accounting total growth due positive currency fluctuations us consumer segment sales billion increase international sales billion increase result operations due currency fluctuations consumer segment sales growth attributable strong sales performance major franchises including overthecounter otc pharmaceutical nutritional products skin care baby kids care overthecounter pharmaceutical nutritional products sales billion increase overall growth franchise primarily resulted rapid increase splenda calorie sweetener tabletop category acquisition merck 's equity stake european nonprescription pharmaceutical business also contributing factor increase added growth overthecounter pharmaceuticals nutritionals franchise major consumer franchise sales table caption change ' vs ' vs millions dollars ' ' c c c c c otc pharmaceuticals nutritionals skin care women 's health baby kids care total table february company announced agreement tate lyle related production sucralose splenda brand transaction completed april resulted company responsible worldwide sales marketing tabletop category splenda brand sweetener tate lyle responsible manufacturing sucralose marketing ingredient sales transaction reduced sales growth franchise skin care franchise sales billion representing increase attributable doubledigit sales growth roc aveeno clean clear neutrogena brand products advanced solutions product line launched key contributor growth neutrogena baby kids care franchise grew billion growth franchise led success johnson 's softwash softlotion product lines balmex brand products acquired consumer segment sales billion increase operational growth accounting total growth due positive currency impact us sales increased international sales increased due operational gains positive currency impact consumer segment sales billion increase increase due operational growth offset negative currency impact us sales increased international sales gains operational gains offset negative currency impact pharmaceutical segment pharmaceutical segment sales billion increase change due operational growth remaining increase related positive impact currency us pharmaceutical segment sales increased international pharmaceutical segment sales increased included operational growth related positive impact currency pharmaceutical segment sales include benefit adjustments related previously estimated performancebased rebate allowances managed care contracts adjustments made based review actual performance levels achieved customers compared expected performance levels favorable adjustments amounted less pharmaceutical segment 's operational growth vast majority impact adjustment hormonal contraceptive franchisepharmaceutical segment sales growth reflects strong performance many key pharmaceutical products partially offset sales decline procrit epoetin alfa eprex epoetin alfa adversely affected competition combined procrit eprex sales declined compared procrit sales declined procrit sales decrease due lower pricing market share partially offset market growth company continues efforts stabilize market share expand market strong growth driver pharmaceutical segment risperdal risperidone medication treats symptoms schizophrenia risperdal accounted billion sales continued success risperdal consta risperidone longacting injection remicade infliximab novel monoclonal antibody therapy indicated treat symptoms crohn 's disease rheumatoid arthritis also strong growth remicade sales billion increase duragesic fentanyl transdermal system novel delivery system treatment chronic pain continued achieve outstanding results growing pediatric exclusivity duragesic patent expired us january first generic version duragesic launched additionally authorized generic version duragesic currently marketed company company expects duragesic sales decline see note discussion regarding matter topamax topiramate antiepileptic recently approved use prevention migraines strong growth levaquin levofloxacin floxin ofloxacin grew fiscal fourth quarter levaquin oral solution approved new day formulation treatment adults currently approved indications anthrax prophylaxis major pharmaceutical product revenues table caption change ' vs ' vs millions dollars ' ' c c c c c procriteprex epoetin alfa risperdal risperidone remicade infliximab duragesic fentanyl transdermal system topamax topiramate levaquinfloxin levofloxacinofloxacin hormonal contraceptives aciphexpariet rabeprazole sodium total table hormonal contraceptive franchise accounted billion sales strong growth ortho evra norelgestrominethinyl estradiol first contraceptive patch approved fda ortho tricyclen lo norgestimateethinyl estradiol low dose oral contraceptive sales increases partially offset reduced sales ortho tricyclen norgestimateethinyl estradiol result generic competition also strong growth various products including velcade bortezomib oncology treatment ditropan xl oxybutynin treatment overactive bladder reminyl galantamine hbr treatment patients mild moderate alzheimer 's disease natrecor nesiritide novel agent approved congestive heart failure concerta methylphenidate hcl product treatment attention deficit hyperactivity disorder sales continued grow despite lack patent exclusivity us present fda approved generic version substitutable concerta abbreviated new drug applications andasfor generic versions concerta pending may approved time pharmaceutical segment sales billion increase change due operational growth remaining increase related positive impact currency us pharmaceutical segment sales increased international pharmaceutical segment sales increased included growth operationally related positive impact currency pharmaceutical segment sales billion increase due operational growth due currency fluctuations us sales increased international sales grew included positive impact currency operational growth medical devices diagnostics segment worldwide medical devices diagnostics segment achieved sales billion representing increase prior year operational growth positive impact currency us sales increased international sales increased operations currency strong sales growth medical devices diagnostics segment led multiple franchises depuy franchise reported billion sales represents growth prior year doubledigit growth depuy 's orthopaedic joint reconstruction unit led increase franchise strong performance also reported depuy 's spine unit mitek sports medicine products cordis franchise key contributor segment results reported sales billion increase prior year primary driver sales growth cypher sirolimuseluting stent international markets including launch japan us cypher sirolimuseluting stent sales remained relatively flat compared due entry competing product biosense webster endovascular business unit also contributed success cordis franchise continued solid doubledigit growth april july cordis cardiology division cordis corporation received warning letters fda regarding good manufacturing practice regulations good clinical practice regulations observations followed postapproval site inspections completed early including sites involved production cypher sirolimuseluting stent response warning letters cordis met periodically fda representatives center districts advising progress made addressing observations raised warning letters ethicon endosurgery franchise reported billion sales representing growth prior year growth mainly driven endocutter sales include products used performing bariatric procedures treatment obesity important focus area franchise ethicon endosurgery introduced new endopath xcel trocar platform contour curved cutter stapler curvilinear cutter stapler colorectal surgery conforms patient 's natural anatomy strong doubledigit sales advanced sterilization products line also key contributor overall sales growth ethicon endosurgery franchise ethicon worldwide franchise achieved billion sales representing growth prior year ethicon franchise continues grow introducing new products marketplace coated vicryl polyglactin plus first product new antibacterial suture platform multipass needles introduced second fiscal quarter major medical devices diagnostics franchise sales table caption change ' vs ' vs millions dollars ' ' c c c c c depuy cordis ethicon endosurgery ethicon lifescan vision care orthoclinical diagnostics total table lifescan franchise reported billion sales growth rate prior year onetouch ultra test strip provided strong growth franchise vision care franchise achieved billion sales growth rate prior year led continued success acuvue advance brand contact lenses hydraclear day acuvue orthoclinical diagnostics franchise reported billion sales representing growth prior year growth mainly driven market penetration automated blood typing products coupled continued growth eci product line december johnson johnson announced signing definitive agreement acquire guidant corporation guidant world leader treatment cardiac vascular disease billion fully diluted equity value medical devices diagnostics segment achieved sales billion representing increase prior year operational growth positive impact currency us sales increased international sales increased operations currency medical devices diagnostics segment sales billion representing total increase total increase also represents operational sales increase prior year currency impact us sales international sales increased prior year analysis consolidated earnings provision taxes income consolidated earnings provision taxes income increased billion billion increase billion percent sales consolidated earnings provision taxes income representing increase decline improvement sections follow highlight significant components changes consolidated earnings provision taxes income cost products sold selling marketing administrative expenses cost products sold selling marketing administrative expenses percent sales follows table caption sales c c c cost products sold percent increasedecrease prior year selling marketing administrative expenses percent increasedecrease prior year table decrease percent sales cost products sold due favorable mix well cost improvement initiatives also decrease percent sales selling marketing administrative expenses due company 's focus managing expenses partially offset increase investment spending across number businesses focused driving future growth improvement percent sales selling marketing administrative expenses increase percent sales cost products sold due changes mix products varying cost structures well cost retirement enhancement program million expensed fourth quarter decreases attributable expense leveraging sales increases productivity improvements research development research activities represent significant part company 's business expenditures relate development new products improvement existing products technical support products compliance governmental regulations protection consumerworldwide costs research activities excluding inprocess research development charges follows table caption millions dollars c c c research expense percent increase prior year percent sales table research development expense percent sales pharmaceutical segment combined consumer medical devices diagnostics segments averaged respectively significant research activities continued pharmaceutical segment increasing billion compound annual growth rate approximately fiveyear period since johnson johnson pharmaceutical research development llc centocor inc alza corporation tibotecvirco nv scios inc primary research centers company inprocess research development company recorded inprocess research development iprd charges million tax result acquisition us commercial rights certain patents knowhow field sedation analgesia scott lab inc charge included operating profit medical devices diagnostics segment company recorded iprd charges million tax related acquisitions scios inc link spine group inc certain assets orquest inc dimensional pharmaceuticals inc scios inc biopharmaceutical company marketed product cardiovascular disease research projects focused autoimmune diseases acquisition scios inc accounted million tax iprd charges included operating profit pharmaceutical segment link spine group inc acquired provide company exclusive worldwide rights charite artificial disc treatment spine disorders acquisition link spine group inc accounted million tax iprd charges included operating profit medical devices diagnostics segment orquest inc biotechnology company focused developing biologicallybased implants orthopaedic spine surgery acquisition certain assets orquest inc accounted million tax iprd charges included operating profit medical devices diagnostics segment dimensional pharmaceuticals inc company technology platform focused discovery development potential new drugs early stage development inflammation acquisition dimensional pharmaceuticals inc accounted million tax iprd charges included operating profit pharmaceutical segment company recorded iprd charges million tax related acquisitions tibotecvirco nv privatelyheld biopharmaceutical company focused developing antiviral treatments obtech medical ag privately held company markets adjustable gastric band treatment morbid obesity iprd million million included pharmaceutical medical devices diagnostics segments respectively income expense net income expense includes gains losses related sale writedown certain investments equity securities held johnson johnson development corporation gains losses disposal fixed assets currency gains losses minority interests litigation settlement income expense royalty income change net income expense increase expense million expense balance million included several expense items none individually significant offset royalty income income million included favorable ruling stent patent settlement million amount received fourth quarter included medical devices diagnostics segment operating profit also included medical devices diagnostics segment operating profit gain sale various product lines longer compatible segment 's strategic goals income expensefor also included recovery million loan included pharmaceutical segment operating profit expense million included impact amgen arbitration settlement expense gain sale ortho prefest product line october arbitrator chicago denied effort amgen inc terminate license agreement ortho biotech inc obtained exclusive us rights amgendeveloped erythropoetin epo indications outside kidney dialysis decision arbitrator found sales made markets amgen retained exclusive rights warrant extraordinary remedy terminating contract instead found amgen could adequately compensated monetary damages arbitrator awarded million damages january arbitrator ruled amgen prevailing party arbitration entitling award reasonable attorney 's fees costs company expensed million fourth quarter connection claim charges included pharmaceutical segment operating profit operating profit segment operating profits segment business follows table caption percent segment sales millions dollars c c c c consumer pharmaceutical med devices diag segments total expenses allocated segments earnings provision taxes income table amounts allocated segments include interest incomeexpense minority interest general corporate income expense graph consumer segment consumer segment operating profit increased previous year percent sales experienced decrease primarily due additional investment consumer promotions advertising overthecounter pharmaceuticals nutritionals franchises operating profit consumer segment percent sales remained unchanged expense leveraging due increased sales volumes offset costs incurred manufacturing programs gain future efficiencies advertising pharmaceutical segment pharmaceutical segment operating profit increased reflects operating profit percent sales improvement change primarily due impact million iprd expenses additionally pharmaceutical segment leveraging result selling marketing related cost improvements operating profit pharmaceutical segment percent sales reflecting decline due iprd charges related acquisitions previously noted additionally operating profit impacted sales decline procrit eprex increased consumer promotional spending new products line extensions medical devices diagnostics segment medical devices diagnostics segment operating profit increased increase prior year achieved improved gross margins resulting cost reduction programs product mix impact million iprd expenses related acquisitions operating profit medical devices diagnostics segment percent sales reflecting improvement interest income expense interest income increased million due primarily higher cash balance cash marketable securities combined balance end billion averaged billion significantly higher billion average cash balance interest expense decreased million compared primarily due decrease average debt balance billion billion provision taxes income worldwide effective income tax rate increase effective tax rate primarily due million tax cost intended repatriation undistributed international earnings associated american jobs creation act added effective income tax rate increase primarily due company 's nondeductible iprd charges increase income subject tax us refer note additional information liquidity capital resources cash flows cash generated operations selected borrowings provide major sources funds growth business including working capital capital expenditures acquisitions uses cash include share repurchases dividends debt repayments cash flow operations billion increase billion increase cash generated operations result net income increase billion net noncash impact iprd charges net cash used investing activities decreased billion due decrease acquisition activity detailed discussion mergers acquisitions see note net cash used financing activities increased billion primarily due increase net repayment debt increased dividends cash current marketable securities billion end compared billion end graph cash generated operations amounted billion billion cash generated operations billion major factors contributing increase increase net income billion net noncash impact iprd charges increase change accounts payable accrued liabilities billion decrease pension funding billion changes deferred taxes billion financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value existing foreign currency assets liabilities hedge future foreign currency product costs gains losses contracts offset gains losses underlying transactions appreciation us dollar january market rates would increase unrealized value company 's forward contracts million conversely depreciation us dollar january market rates would decrease unrealized value company 's forward contracts million either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future earnings cash flows company hedges exposure fluctuations currency exchange rates effect certain assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates company 's interest rate sensitive financial instruments would either increase decrease unrealized value company 's swap contracts approximately million either scenario maturity gain loss swap contract would offset gain loss underlying assets liabilities therefore would impact future cash flows company enter financial instruments trading speculative purposes company policy entering contracts withparties least equivalent credit rating counterparties contracts major financial institutions company significant exposure one counterparty management believes risk loss related nonperformance counterparty remote total unused credit available company approximates billion including billion credit commitments billion expire september billion expire september also included billion uncommitted lines various banks worldwide expire total borrowings end billion billion respectively total debt represented total capital shareholders ' equity total debt total capital shareholders ' equity per share end compared yearend increase november company exercised right redeem million aggregate principal amount debentures due redemption price principal amount per principal amount debentures accrued interest date redemption january material cash commitments johnson johnson continues one industrial companies triple credit rating summary borrowings found note contractual obligations commitments company longterm contractual obligations primarily lease debt obligations unfunded retirement plans significant obligations satisfy obligations company use cash operations following table summarizes company 's contractual obligations aggregate maturities january see notes details table caption unfunded operating debt retirement millions dollars leases obligations plans c c c c table amounts include interest expense share repurchase dividends february company announced stock repurchase program billion time limit program program completed august million shares repurchased addition company annual program repurchase shares use employee stock incentive plans company increased dividend nd consecutive year cash dividends paid per share compared dividends per share per share dividends distributed follows table caption c c c first quarter second quarter third quarter fourth quarter total table january board directors declared regular cash dividend per share paid march shareholders record offebruary company expects continue practice paying regular cash dividends information critical accounting policies estimates management 's discussion analysis results operations financial condition based company 's consolidated financial statements prepared accordance accounting principles generally accepted us preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company believes understanding certain key accounting policies essential achieving insight company 's operating results financial condition key accounting policies include revenue recognition income taxes legal self insurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock options revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates largest medicaid rebate provision estimated based sales terms historical experience trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler third party sellthrough market research data well internally generated information sales returns generally estimated recorded based historical sales returns information analysis recent wholesale purchase information consideration stocking levels wholesalers forecasted demand amounts products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting accruals company also recognizes service revenue received copromotion certain products years presented service revenues less total revenues included sales customers income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting us tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based current tax regulations rates changes tax laws rates may affect recorded deferred tax assets liabilities future management believes changes estimates would result material effect company 's results operations cash flows financial position company determined repatriate billion undistributed international earnings accordance american jobs creation act recorded tax charge million fourth quarter tax charge may reduced approximately million due technical corrections legislation expected considered congress legislation passed fourth quarter permits us corporations repatriate earnings foreign subsidiaries special onetime favorable effective tax rate january december cumulative amount undistributed international earnings approximately billion billion respectively company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded cover undistributed portion intended repatriation legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability cases arise normal course business accruals based management 's judgment probability losses opinions legal counsel whereapplicable actuarially determined estimates additionally company records insurance receivable amounts third party insurers based probability recovery appropriate reserves receivables recorded estimated amounts may collected third party insurers longlived intangible assets company assesses changes economic conditions makes assumptions regarding estimated future cash flows evaluating value company 's property plant equipment goodwill intangible assets assumptions estimates may change time may may necessary company record impairment charges certain tangible intangible assets written fair value resulting charge recorded cost products sold employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans based assumptions discount rate expected return plan assets expected salary increases health care cost trend rates see note detail rates effect rate change would company 's results operations stock options company elected use accounting principles board opinion accounting stock issued employees apb require compensation costs related stock options charged net income options granted various stock options plans exercise price equal market value underlying common stock grant date statement financial accounting standard sfas accounting stockbased compensation transition disclosure amendment fasb statement requires pro forma disclosure net income earnings per share determined fair value method accounting stock options applied measuring compensation cost see notes information regarding stock options new accounting standards june fasb issued sfas accounting costs associated exit disposal activities effective exit disposal activities initiated december company 's adoption sfas material effect company 's results operations cash flows financial position november fasb issued fasb interpretation fin guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others interpretation fasb statements rescission fasb interpretation fin clarifies requirements fasb statement accounting contingencies relating guarantor 's accounting disclosure issuance certain types guarantees disclosure requirements fin effective financial statements interim annual periods end december provisions initial recognition measurement effective prospective basis guarantees issued modified december irrespective guarantor 's yearend fin requires upon issuance guarantee entity must recognize liability fair value obligation assumes guarantee company 's adoption fin material effect company 's results operations cash flows financial position january fasb issued fin consolidation variable interest entities interpretation arb december issued revised fin r consolidation variable interest entities interpretation arb address consolidation variable interest entities addition fasb issued various fasb staff positions fsp topic december fin expands criteria consideration determining whether variable interest entity consolidated business entity requires existing unconsolidated variable interest entities include limited special purpose entities spes consolidated primary beneficiaries entities effectively disperse risks among parties involved interpretation immediately applicable variable interest entities created january adoption portion fin material effect company 's results operations cash flows financial position fin applicable variable interest entities enterprise holds variable interest acquired february adoption portion fin material effect results operations cash flows financial position company april fasb issued sfas amendment statement derivative instruments hedging activities effective contracts entered modified june statement amends clarifies financial accounting reporting derivative instruments including certain derivative instruments embedded contracts hedging activities company 's adoption sfas material effect company 's results operations cash flows financial position december fasb issued fsp fas accounting disclosure requirements related medicare prescription drug improvement modernization act effective interim annual financial statements fiscal years ending december company elected defer adoption fsp fas authoritative guidance issued allowed standard guidance issued fasb may via fsp fas company adopted fsp fas fiscal third quarter adoption material effect company 's results operations cash flows financial position july fasb ratified eitf consensus issue whether investor apply equity method accounting investments common stock effective fourth quarter consensus clarifies investor ability exercise significant influence operating financial policies investee equity method accounting applied investor investment common stock andor investment insubstance common stock adoption consensus material effect company 's results operations cash flows financial position october fasb ratified eitf consensus issue accounting preexisting relationships parties business combination consensus describes accounting settlement preexisting relationships reacquisition certain rights business combination consensus effective fourth quarter adopted company quarter adoption material effect company 's results operations cash flows financial position may impact future transactions november fasb issued sfas inventory costs amendment arb statement clarifies accounting idle capacity expense freight handling costs wasted material effective third quarter company believes adoption statement material effect results operations cash flows financial position december fasb issued sfas r share based payment statement establishes standards accounting transactions entity exchanges equity instruments goods services focuses primarily accounting transactions entity obtains employee services sharebased payment transactions employee stock options statement requires measurement cost employee services received exchange award equity instruments employee stock options fair value grant date cost recognized period employee required provide services exchange award requisite service period effective date statement fiscal third quarter company still considering transition methods standard company currently estimates annualized cost associated expensing stock options approximately per share refer note details company proposing new longterm incentive plan including various forms stock compensation stock options restricted stock december fasb issued sfas exchanges nonmonetary assets amendment apb statement clarifies nonmonetary transactions commercial substance recorded fair value effective first quarter company believes adoption statement material effect results operations cash flows financial position december fasb issued fsp fas fas address accounting disclosure requirements related certain provisions american jobs creation act requirements effective immediately company adopted provisions impact fully described note economic market factors johnson johnson aware products used environment decade policymakers consumers businesses expressed concerns rising cost health care response concerns johnson johnson long standing policy pricing products responsibly period united states weighted average compoundannual growth rate johnson johnson net price increases health care products prescription overthecounter drugs hospital professional products us consumer price index cpi inflation rates even though moderate many parts world continue effect worldwide economies consequently way companies operate face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases company faces various worldwide health care changes may result pricing pressures include health care cost containment government legislation relating sales promotions reimbursement company also operates environment become increasingly hostile intellectual property rights generic drug firms filed abbreviated new drug applications seeking market generic forms company 's key pharmaceutical products prior expiration applicable patents covering products event company successful defending lawsuit resulting abbreviated new drug application filing generic firms introduce generic versions product issue resulting potential substantial market share revenue loss product information see discussion litigation filers abbreviated new drug applications note common stock market prices company 's common stock listed new york stock exchange symbol jnj composite market price ranges johnson johnson common stock table caption high low high low c c c c first quarter second quarter third quarter fourth quarter yearend close table legal proceedings company involved numerous product liability cases united states many concern adverse reactions drugs medical devices damages claimed substantial company confident adequacy warnings instructions use accompany products feasible predict ultimate outcome litigation however company believes liability results cases substantially covered existing amounts accrued company 's balance sheet selfinsurance program third party product liability insurance see note information regarding legal proceedings cautionary factors may affect future results annual report contains forwardlooking statements forwardlooking statements relate strictly historical current facts anticipate results based management 's plans subject uncertainty forwardlooking statements may identified use words like plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance company 's strategy growth product development regulatory approval market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially company 's expectations projections investors therefore cautioned place undue reliance forwardlooking statements company assumes obligation update forwardlooking statements result new information future events developmentsrisks uncertainties include general industry conditions competition economic conditions interest rate currency exchange rate fluctuations technological advances new products patents attained competitors challenges inherent new product development including obtaining regulatory approvals challenges patents us foreign health care reforms governmental laws regulations trends toward health care cost containment increased scrutiny health care industry government agencies product efficacy safety concerns resulting product recalls regulatory action company 's report year ended january contains exhibit discussion additional factors could cause actual results differ expectations company notes factors permitted private securities litigation reform act consolidated balance sheets johnson johnson subsidiaries january december dollars millions except share per share data note table caption c c assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes income note prepaid expenses receivables total current assets marketable securities noncurrent notes property plant equipment net notes intangible assets net notes deferred taxes income note assets note total assets liabilities shareholders ' equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued salaries wages commissions accrued taxes income total current liabilities longterm debt note deferred tax liability note employee related obligations notes liabilities total liabilities shareholders ' equitypreferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares note receivable employee stock ownership plan note accumulated comprehensive income note retained earnings less common stock held treasury cost note total shareholders ' equity total liabilities shareholders ' equity table see notes consolidated financial statements consolidated statements earnings johnson johnson subsidiaries dollars millions except per share figures note table caption c c c sales customers cost products sold gross profit selling marketing administrative expenses research expense purchased inprocess research development note interest income interest expense net portion capitalized note income expense net earnings provision taxes income provision taxes income note net earnings basic net earnings per share notes diluted net earnings per share notes table see notes consolidated financial statements consolidated statements equity johnson johnson subsidiaries dollars millions note table caption note receivable employee compre stock owner hensive retained ship plan total income earnings esop c c c c bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock comprehensive income net tax currency translation adj unrealized losses securities pension liability adjustment losses derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock business combinations comprehensive income net tax currency translation adj unrealized gains securities pension liability adj losses derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock comprehensive income net tax currency translation adj unrealized gains securities pension liability adj gains derivatives hedges reclassification adj total comprehensive income note receivable esop bal jan table table caption accumul common compre stock treasury hensive issued stock income amount amount c c c bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock comprehensive income net tax currency translation adj unrealized losses securities pension liability adjustment losses derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock business combinations comprehensive income net tax curncy translation adj unrealized gains securities pension liability adj losses derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase commonstock comprehensive income net tax currency translation adj unrealized gains securities pension liability adj gains derivatives hedges reclassification adj total comprehensive income note receivable esop bal jan table see notes consolidated financial statements consolidated statements cash flows johnson johnson subsidiaries dollars millions note table caption c c c cash flows operating activities net earnings adjustments reconcile net earnings cash flows depreciation amortization property intangibles purchased inprocess research development deferred tax provision accounts receivable allowances changes assets liabilities net effects acquisition businesses increase accounts receivable decreaseincrease inventories increase accounts payable accrued liabilities increase current noncurrent assets increase current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisition businesses net cash acquired note purchases investments sales investments net cash used investing activities cash flows financing activitiesdividends shareholders repurchase common stock proceeds short term debt retirement short term debt proceeds long term debt retirement long term debt proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisition businesses fair value assets acquired fair value liabilities assumed net cash paid acquisitions table see notes consolidated financial statements notes consolidated financial statements summary significant accounting principles principles consolidation consolidated financial statements include accounts johnson johnson subsidiaries intercompany accounts transactions eliminated description company business segments company subsidiaries approximately employees worldwide engaged manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing new accounting pronouncements june fasb issued sfas accounting costs associated exit disposal activities effective exit disposal activities initiated december company 's adoption sfas material effect company 's results operations cashflows financial position november fasb issued fasb interpretation fin guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others interpretation fasb statements rescission fasb interpretation fin clarifies requirements fasb statement accounting contingencies relating guarantor 's accounting disclosure issuance certain types guarantees disclosure requirements fin effective financial statements interim annual periods end december provisions initial recognition measurement effective prospective basis guarantees issued modified december irrespective guarantor 's yearend fin requires upon issuance guarantee entity must recognize liability fair value obligation assumes guarantee company 's adoption fin material effect company 's results operations cash flows financial position january fasb issued fin consolidation variable interest entities interpretation arb december issued revised fin r consolidation variable interest entities interpretation arb address consolidation variable interest entities addition fasb issued various fasb staff positions fsp topic december fin expands criteria consideration determining whether variable interest entity consolidated business entity requires existing unconsolidated variable interest entities include limited special purpose entities spes consolidated primary beneficiaries entities effectively disperse risks among parties involved interpretation immediately applicable variable interest entities created january adoption portion fin material effect company 's results operations cash flows financial position fin applicable variable interest entities enterprise holds variable interest acquired february adoption portion fin material effect results operations cash flows financial position company april fasb issued sfas amendment statement derivative instruments hedging activities effective contracts entered modified june statement amends clarifies financial accounting reporting derivative instruments including certain derivative instruments embedded contracts hedging activities company 's adoption sfas material effect company 's results operations cash flows financial position december fasb issued fsp fas accounting disclosure requirements related medicare prescription drug improvement modernization act effective interim annual financial statements fiscal years ending december company elected defer adoption fsp fas authoritative guidance issued allowed standard guidance issued fasb may via fsp fas company adopted fsp fas fiscal third quarter adoption material effect company 's results operations cash flows financial position july fasb ratified eitf consensus issue whether investor apply equity method accounting investments common stock effective fourth quarter consensus clarifies investor ability exercise significant influence operating financial policies investee equity method accounting applied investor investment common stock andor investment insubstance common stock adoption consensus material effect company 's results operations cash flows financial position october fasb ratified eitf consensus issue accounting preexisting relationships parties business combination consensus describes accounting settlement preexisting relationships reacquisition certain rights business combination consensus effective fourth quarter adopted company quarter adoption material effect company 's results operations cash flows financial position may impact future transactionsin november fasb issued sfas inventory costs amendment arb statement clarifies accounting idle capacity expense freight handling costs wasted material effective third quarter company believes adoption statement material effect results operations cash flows financial position december fasb issued sfas r share based payment statement establishes standards accounting transactions entity exchanges equity instruments goods services focuses primarily accounting transactions entity obtains employee services sharebased payment transactions employee stock options statement requires measurement cost employee services received exchange award equity instruments employee stock options fair value grant date cost recognized period employee required provide services exchange award requisite service period effective date statement fiscal third quarter company still considering transition methods standard company currently estimates annualized cost associated expensing stock options approximately per share company proposing new longterm incentive plan including various forms stock compensation stock options restricted stock december fasb issued sfas exchanges non monetary assets amendment apb statement clarifies nonmonetary transactions commercial substance recorded fair value effective first quarter company believes adoption statement material effect results operations cash flows financial position december fasb issued fsp fas fas address accounting disclosure requirements related certain provisions american jobs creation act requirements effective immediately company adopted provisions impact described note note cash equivalents company considers securities maturities three months less purchased cash equivalents investments shortterm marketable securities carried cost approximates fair value longterm debt securities company ability intent hold maturity carried amortized cost also approximates fair value investments classified availableforsale carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company periodically reviews investments nonmarketable equity securities impairment adjusts investments fair value decline market value deemed temporary property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets building building equipment years land leasehold improvements years machinery equipment years company capitalizes certain computer software development costs included machinery equipment incurred connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows necessary charges impairments longlivedassets recorded amount present value future cash flows less carrying value assets revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates largest medicaid rebate provision estimated based sales terms historical experience trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler third party sellthrough market research data well internally generated information sales returns generally estimated recorded based historical sales returns information analysis recent wholesale purchase information consideration stocking levels wholesalers forecasted demand amounts products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting accruals company also recognizes service revenue received copromotion certain products sales customers shipping handling shipping handling costs incurred million million million respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presented inventories inventories stated lower cost market determined firstin firstout method goodwill intangible assets effective beginning fiscal year accordance sfas company discontinued amortization relating existing goodwill indefinite lived intangible assets nonamortizable sfas requires goodwill nonamortizable intangible assets assessed annually impairment company completed annual impairment test fiscal fourth quarter impairment determined future impairment tests performed fiscal fourth quarter annually intangible assets finite useful lives continue amortized useful lives reviewed impairment warranted economic conditions see note details intangible assets financial instruments company follows provisions sfas accounting derivative instruments hedging activities amended sfas accounting certain derivative instruments certain hedging activities sfas amendment statement derivative instruments hedging activities collectively referred sfas sfas requires derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction company uses forward exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany product third party purchases raw materials denominated foreign currency company also uses currency swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company uses forward exchange contracts offset exposure certain foreign currency assets liabilities forward exchange contracts designated hedges therefore changes fair values derivatives arerecognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities designation cash flow hedge made entrance date derivative contract inception derivatives expected highly effective changes fair value derivative designated cash flow hedge highly effective recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction fair value forward exchange contract represents present value change forward exchange rates times notional amount derivative fair value currency swap contract determined discounting present future cash flows currencies exchanged interest rates prevailing market periods currency exchanges due expressing result us dollars current spot foreign currency exchange rate ongoing basis company assesses whether derivative continues highly effective offsetting changes cash flows hedged items derivative longer expected highly effective hedge accounting discontinued hedge ineffectiveness included current period earnings insignificant company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposure 's impact company 's financial performance protect company 's cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically additional information becomes available receivables insurance recoveries related product liability claims recorded undiscounted basis probable recovery realized research development research development expenses expensed incurred upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion income taxes company determined repatriate billion undistributed international earnings accordance american jobs creation act recorded tax charge million fourth quarter tax charge may reduced approximately million due technical corrections legislation expected considered congress legislation passed fourth quarter permits us corporations repatriate earnings foreign subsidiaries special onetime favorable effective tax rate january december cumulative amount undistributed international earnings approximately billion billion respectively company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded cover undistributed portion intended repatriation deferred income taxes recognized tax consequences temporary differences applying enacted statutory tax rates applicable future years differences financial reporting tax basis existing assets liabilities net earnings per sharebasic earnings per share computed dividing net income available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities exercised converted common stock using treasury stock method stock options january company stockbased employee compensation plans described note company accounts plans recognition measurement principles accounting principle board opinion accounting stock issued employees apb related interpretations compensation costs recorded net income stock options options granted plans exercise price equal market value underlying common stock date grant required sfas accounting stockbased compensation transition disclosure amendment fasb statement following table shows estimated effect net income earnings per share company applied fair value recognition provision sfas accounting stockbased compensation stockbased employee compensation table caption dollars millions except per share data c c c net income reported less compensation expense pro forma earnings per share basic reported pro forma diluted reported pro forma table determined fair value based method awards net tax use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported estimates used accounting sales discounts rebates allowances incentives product liabilities depreciation amortization employee benefits contingencies asset liability valuations instance determining annual pension postemployment benefit costs company estimates rate return plan assets cost future health care benefits actual results may may differ estimates annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years fiscal year consists weeks case reclassification certain prior year amounts reclassified conform current year presentation inventories end inventories comprised table caption dollars millions c c raw materials supplies goods process finished goods table property plant equipment end property plant equipment cost accumulated depreciation table caption dollars millions c c land land improvements buildings building equipment machinery equipment construction progress less accumulated depreciation table company capitalizes interest expense part cost construction facilities equipment interest expense capitalized million million million respectively depreciation expense including amortization capitalized interest billion billion billion respectively upon retirement disposal fixed assets cost related amount accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds recorded earnings rental expense lease commitments rentals space vehicles manufacturing equipment office data processing equipment operating leases approximately million million million approximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year january table caption dollars millions total c c c c c c c table commitments capital leases significant employee related obligations end employee related obligations table caption dollars millions c c pension benefits postretirement benefits postemployment benefits deferred compensation less current benefits payable employee related obligations table prepaid employee related obligations million million respectively included assets consolidated balance sheet borrowings components longterm debt follows table caption effective effective dollars millions rate rate c c c c zero coupon convertible subordinated debentures due debentures due debentures due debentures due notes due debentures due eurodollar notes due notes due convertible subordinated notes due industrial revenue bonds less current portion table weighted average effective rate debentures redeemed november company access substantial sources funds numerous banks worldwide total unused credit available company approximates billion including billion credit commitments billion expire september billion expire september also included billion uncommitted lines various banks worldwide expire interest charged borrowings credit line agreements based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreement material company filed shelf registration securities exchange commission became effective january enables company issue billion debt securities warrants purchase debt securities debt issued shelf full amount remained available january august scios inc issued private offering million convertible subordinated notes due interest payable semiannually february august notes convertible option holder time prior redemption repurchase maturity conversion price following acquisition johnson johnson april principal amount notes became convertible right receive cash without interest semiannual interest remains payable conversion repurchase maturity january book value notes approximates fair value july alza corporation completed private offering zero coupon convertible subordinated debentures issued price per principal amount maturity january outstanding debentures total principal amount maturity million yield maturity per annum computed semiannual bond equivalent basis periodic interest payments terms debentures holders entitled convert debentures approximately million shares johnson johnson stock price per share approximately million shares issued january due voluntary conversions note holders option holder debentures may repurchased company july purchase price equal issue price plus accreted original issue discount purchase date company option may elect deliver either johnson johnson common stock cash combination stock cash event repurchase debentures company option may also redeem debentures july atthe issue price plus accreted original issue discount january december fair value based quoted market value debentures million million respectively november company exercised right redeem million aggregate principal amount debentures due redemption price principal amount per principal amount debentures accrued interest date redemption shortterm borrowings current portion longterm debt amounted million end principally local borrowing international subsidiaries aggregate maturities longterm obligations commencing table caption dollars millions c c c c c c table intangible assets end gross net amounts intangible assets table caption dollars millions c c goodwill gross less accumulated amortization goodwill net trademarks nonamortizable gross less accumulated amortization trademarks nonamortizable net patents trademarks gross less accumulated amortization patents trademarks net intangibles gross less accumulated amortization intangibles net total intangible assets gross less accumulated amortization total intangible assets net table goodwill january allocated segments business follows table caption med dev dollars millions consumer pharm diag total c c c c goodwill net accumulated amortization december acquisitions translation goodwill january tablethe weighted average amortization periods patents trademarks intangible assets years years respectively amortization expense amortizable intangible assets fiscal year ended january million tax certain patents intangibles written fair value resulting charge included amortization expense estimated amortization expense five succeeding years approximates million tax per year substantially amortization expense included cost products sold income taxes provision taxes income consists table caption dollars millions c c c currently payable us taxes international taxes deferred us taxes international taxes table comparison income tax expense federal statutory rate company 's effective tax rate follows table caption dollars millions c c c us international earnings taxes income tax rates statutory puerto rico ireland operations research tax credits us state local international subsidiaries excluding ireland repatriation international earnings iprd effective tax rate table company subsidiaries operating puerto rico various tax incentive grants addition company subsidiaries manufacturing ireland incentive tax rate american jobs creation act tax legislation permits us corporations repatriate earnings foreign subsidiaries special onetime favorable effective federal tax rate versus consideration foreign taxes paid company determined repatriate approximately billion company accrued million federal state taxes attributable repatriation earnings tax charge may reduced approximately million due technical corrections legislation expected considered congress increase worldwide effective tax rate primarily due repatriation foreign earnings legislation added effective tax rate temporary differences carry forwards follows table caption deferred tax deferred tax dollars millions asset liability asset liability c c c cemployee related obligations depreciation nondeductible intangibles international rd capitalized tax reserves liabilities income reported tax purposes miscellaneous international capitalized intangibles miscellaneous us total deferred income taxes table difference net deferred tax income per balance sheet net deferred tax included taxes income balance sheet international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years substantial portion cash flows local currency consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income equity account includes results translating balance sheet assets liabilities current exchange rates except located highly inflationary economies reflected operating results analysis changes foreign currency translation adjustments included note net currency transaction translation gains losses included expense losses million million million respectively common stock stock option plans stock compensation agreements january company stockbased compensation plans stock option plan company may grant options employees issued shares company 's common stock plus number shares available previous year issued well shares issued plan expired terminated without exercised shares outstanding contracts company 's stock option plans nonemployee director 's plan cordis biosense gynecare centocor innovasive devices alza inverness scios stock option plans options granted plans except stock option plan stock options expire years date granted vest service periods range one five years options granted current market price date grant shares available stock option plan future grants based issued shares year million shares could granted year years addition available shares described shares available future grants plan million end summary status company 's stock option plans january december december changes years ending dates presented table caption weighted options average shares thousands outstanding exercise price c c balance december options granted options exercised options canceledforfeited balance december options granted options exercised options canceledforfeited balance december options granted options exercised options canceledforfeited balance january table includes options issued replace scios options outstanding granted prior acquisition average fair value options granted fair value estimated using blackscholes option pricing model based weighted average assumptions table caption c c c riskfree rate volatility expected life yrs yrs yrs dividend yield table following table summarizes stock options outstanding exercisable january table caption shares thousands outstanding exercisable average average exercise average exercise exercise price range options life price options price c c c c c table average contractual life remaining years stock options exercisable december december options average price options average price respectively segments business geographic areas see information segments business geographic areas accumulated comprehensive income components comprehensive incomeloss consist following table caption total unrealized gains accumulated foreign gains pens losses cur losses liab deriv comprehensive dollars millions trans sec adj hedg incloss c c c c c dec changes net changedue hedging transactions net amount reclassed net earnings net changes dec changes net change due hedging transactions net amount reclassed net earnings net changes dec changes net change due hedging transactions net amount reclassed net earnings net changes jan table total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million tax effect unrealized gainslosses equity securities expense million expense million benefit million tax effect gainslosses derivatives hedges benefits million million million respectively see note additional information relating derivatives hedging currency translation adjustments currently adjusted income taxes relate permanent investments international subsidiaries pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care us retired employees dependents many international employees covered governmentsponsored programs cost company significant retirement plan benefits primarily based employee 's compensation last three five years retirement number years service international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company fund retiree health care benefits advance right modify plans future company uses date consolidated financial statements january december respectively measurement date us international retirement benefit plans net periodic benefit cost company 's defined benefit retirement plans benefit plans include following componentstable caption retirement plans benefit plans dollars millions c c c c c c service cost interest cost expected return plan assets amortization prior service cost amortization net transition asset recognized actuarial lossesgains curtailments settlements special termination benefits net periodic benefit cost table net periodic benefit cost attributable us retirement plans million million million company offered voluntary retirement program enhanced benefits called retirement enhancement program rep eligible us regular fulltime employees attained age least years pension credited service june program enhancements included elimination early retirement reduction pension benefit purposes normally per year prior age special termination benefit one week pay per year credited service program resulted onetime increase us pension expense million reflect value retirement enhancement weightedaverage assumptions following table represent rates used develop actuarial present value projected benefit obligation year listed also net periodic benefit cost following year table caption retirement plans us benefit plans c c c c discount rate expected longterm rate return plan assets rate increase compensation levels international benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels table table caption benefit plans us benefit plans c c c c discount rate expected longterm rate return plan assets rate increase compensation levels international benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels table expected longterm rate return plan assets assumptions determined using building block approach considering historical averages realreturns asset class certain countries historical returns meaningful consideration given local market expectations longterm returns following table displays assumed health care trend rates individuals table caption health care plans c c health care trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate table onepercentagepoint change assumed health care cost trend rates would following effect table caption onepercentage onepercentage dollars millions point increase point decrease c c health care plans total interest service cost postretirement benefit obligation table following table sets forth information related benefit obligation fair value plan assets yearend company 's defined benefit retirement plans postretirement plans table caption dollars millions retirement plans benefit plans change benefit obligation c c c c projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial losses divestitures acquisitions curtailments settlements benefits paid plan effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return plan assets company contributions plan participant contributions divestitures benefits paid plan assets effect exchange rates plan assets fair value end year table strategic asset allocations determined country based nature liabilities considering demographic composition plan participants average age years service active versus retiree status company 's plans considered nonmature plans longterm strategic asset allocations consistent types plans emphasis placed diversifying equities broad basis combined currency matching fixed income assets following table displays projected future benefit payments company 's retirement benefit plans table caption dollars millions projected future benefit payments c c c c c c retirement plans benefit plans gross medicare rebates benefit plans net table company expected fund us retirement plans order meet minimum statutory funding requirements international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain countries united states funding pension plans common practice funding provides economic benefit consequently company several pension plans funded following table displays projected future contributions company 's us international unfunded retirement plans table caption dollars millions projected future contributions c c c c c c unfunded us retirement plans unfunded international retirement plans table company 's retirement plan asset allocation end target allocations follows table caption percent target dollars millions plan assets allocation us retirement plans c c c equity securities debt securities total plan assets international retirement plans equity securities debt securities real estate total plan assets table company 's benefit plans unfunded except us life insurancecontract assets million million january december respectively fair value johnson johnson common stock directly held plan assets million total plan assets january million total plan assets december amounts recognized company 's balance sheet consist following table caption retirement plans benefit plans dollars millions c c c c plan assets fair value projected benefit obligation funded status unrecognized actuarial losses unrecognized prior service cost unrecognized net transition asset total recognized consolidated balance sheet book accruals prepaid benefits intangible assets accumulated comprehensive income total recognized consolidated balance sheet table accumulated benefit obligation us international defined benefit retirement plans million million january december respectively minimum pension liability adjustment required actuarial present value accumulated benefits obligation abo exceeds fair value plan assets accrued pension liabilities minimum pension liabilities intangible assets accumulated comprehensive income million million respectively relate primarily plans outside us increase minimum liability included comprehensive income million million respectively plans accumulated benefit obligations excess plan assets consist following table caption retirement plans dollars millions c c accumulated benefit obligation projected benefit obligation plan assets fair value table december medicare prescription drug improvement modernization act enacted introduces prescription drug benefit medicare well subsidy sponsors retiree health care benefit plans company 's prescription plan actuarially equivalent medicare part coverage due fact levels annual claim amounts plan provides greater reimbursement medicare benefit change estimated participation rates per capita claims costs result act company recognized effect subsidy prospective basis june recognition reduces beforetax aftertax expense million apbo million marketable securitiestable caption january unreal amort ized est ized gains fair cost losses value c c c current investments government securities obligations corporate debt securities money market funds time deposits collateralized mortgage obligations asset backed securities bank notes total current marketable securities noncurrent investments marketable securities table table caption december unreal amort ized est ized gains fair cost losses value c c c current investments government securities obligations corporate debt securities money market funds time deposits collateralized mortgage obligations asset backed securities bank notes total current marketable securities noncurrent investments marketable securities table current marketable securities include billion billion classified cash equivalents balance sheet january december respectively financial instruments company follows provisions sfas requiring derivative instruments recorded balance sheet fair value january balance deferred net losses derivatives included accumulated comprehensive income million aftertax additional information see note company expects substantially amount reclassified earnings next months result transactions expected occur period amount ultimately realized earnings differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative transactions third parties cause amount accumulated comprehensive income affect net earnings maximum length time company hedging months year ended january net impact hedges ' ineffectiveness company 's financial statements insignificant company recorded net loss million income expense representing impact discontinuance cash flow hedges probable originally forecasted transactions occur end originally specified time period refer note disclosures movements accumulated comprehensive income concentration credit riskthe company invests excess cash deposits major banks throughout world high quality money market instruments company policy making investments commercial institutions least equivalent credit rating investments generally mature within six months company incurred related losses savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employee 's contributions consistent provisions plan heshe eligible us salaried plan onethird company match paid company stock employee stock ownership plan esop unless employee chose redirect investment establish esop company loaned million esop trust purchase shares company stock open market exchange company received note balance recorded reduction shareholders ' equity remaining shares held esop trust expected allocated participant accounts end february total company contributions plans million million million mergers acquisitions divestitures december johnson johnson announced signing definitive agreement acquire guidant corporation guidant world leader treatment cardiac vascular disease billion fully diluted equity value board directors johnson johnson guidant given respective approvals transaction subject clearance hartscottrodino antitrust improvements act european union merger control regulation customary closing conditions acquisition could result divestiture certain assets operations required regulatory agencies agreement requires approval guidant 's shareholders subject aforementioned approvals acquisition expected close third quarter terms agreement upon close transaction share guidant common stock would exchanged cash johnson johnson common stock provided average johnson johnson common stock price day trading period ending three days prior transaction closing guidant common share exchanged would converted johnson johnson common stock less shares plus cash based guidant 's approximately million common shares outstanding close business december would result issuance approximately million less million shares johnson johnson common stock guidant 's approximately million option shares outstanding close business december would converted options acquire johnson johnson common stock terms conditions applicable guidant 's option plan option shares would convert johnson johnson common stock utilizing floating exchange ratio exchange ratio cash portion option exchange multiple defined agreement plan merger dated december certain businesses acquired million cash million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition addition per terms acquisition agreement link spine group inc million cash paid owners link spine group inc based date us food drug administration fda approved charite artificial disc thus total cash expenditures related acquisition million acquisitions included merck 's interest johnson johnsonmerck consumer pharmaceuticals co european nonprescription pharmaceutical joint venture including infrastructure brand assets managed european joint venture egea biosciences inc exercise option acquire remaining outstanding stock owned johnson johnson developed proprietary technology platform called gene writer allows rapid highly accurate synthesis dna sequences gene assembly construction large synthetic gene librariesartemis medical inc privately held company ultrasound xray visible biopsy site breast markers well hybrid markers us commercial rights certain patents knowhow field sedation analgesia scott lab inc biapharm sas privately held french producer marketer skin care products centered around leading brand biafine assets micomed privately owned manufacturer spinal implants primarily focused supplying german market acquisition ambi skin care brand women color excess purchase price estimated fair value tangible assets acquired amounted million allocated identifiable intangibles goodwill million related us fda approval charite artificial disc recorded additional goodwill associated link spine group inc acquisition thus total additions intangibles goodwill million approximately million identified value inprocess research development iprd associated scott lab acquisition value iprd calculated using cash flow projections discounted risk inherent projects discount rate certain businesses acquired billion cash million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition acquisitions included link spine group inc privately owned corporation exclusive worldwide rights charite artificial disc scios inc biopharmaceutical company marketed product cardiovascular disease research projects focused autoimmune diseases dimensional pharmaceuticals inc company technology platform focused discovery development therapeutic small molecules orapharma inc specialty pharmaceutical company focused development commercialization unique oral therapeutics certain assets orquest inc privately held biotechnology company focused developing biologicallybased implants orthopaedics spine surgery excess purchase price estimated fair value tangible assets acquired amounted billion allocated identifiable intangibles goodwill approximately million identified value inprocess research development iprd primarily associated acquisition link spine group inc scios inc iprd charge related link spine group inc acquisition million associated charite artificial disc charite artificial disc marketed countries outside us premarket approval application filed us food drug administration february value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects probability success factor used reflect inherent clinical regulatory risk discount rate purchase price link spine group inc acquisition allocated tangible identifiable intangible assets acquired liabilities assumed based estimated fair values acquisition date excess purchase price fair values assets liabilities acquired approximately million allocated goodwill substantially amount allocated goodwill deductible tax purposes iprd charge related scios inc million largely associated p kinase inhibitor program value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects using probability success factor discount rate purchase price scios inc acquisition allocated tangible identifiable intangible assets acquired liabilities assumed based estimated fair values acquisition date identifiable intangible assets included patents trademarks valued approximately billion excess purchase price fair values assets liabilities acquired approximately million allocated goodwill substantially amount allocated goodwill deductible tax purposes remaining iprd associated orquest inc dimensional pharmaceuticals inc charges million million respectively cases value iprd calculated assistance third party appraiser certain businesses acquired million cash liabilitiesassumed million acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition acquisitions included tibotecvirco nv privatelyheld biopharmaceutical company focused developing antiviral treatments micro typing systems inc manufacturer reagents supplier distributed instruments known idmicro typing system obtech medical ag privatelyheld company markets adjustable gastric band treatment morbid obesity excess purchase price estimated fair value tangible assets acquired entities amounted million allocated identifiable intangibles goodwill approximately million identified value iprd associated tibotecvirco nv obtech medical ag acquisitions iprd charge related tibotecvirco nv million associated two early stage hiv compounds value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects using probability success factors ranging discount rate iprd charge related obtech medical ag million associated development current swedish adjustable gastric band sagb use united states well development next generation technology platform value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects using probability success factor discount rate supplemental pro forma information per sfas business combinations sfas goodwill intangible assets provided impact aforementioned acquisitions material effect company 's results operations cash flows financial position divestitures material effect company 's results operations cash flows financial position legal proceedings product liability company involved numerous product liability cases united states many concern adverse reactions drugs medical devices damages claimed substantial company confident adequacy warnings instructions use accompany products feasible predict ultimate outcome litigation however company believes liability results cases substantially covered existing amounts accrued company 's balance sheet selfinsurance program third party product liability insurance one group cases company concerns janssen pharmaceutica inc product propulsid cisapride withdrawn general sale restricted limited use wake publicity events numerous lawsuits filed janssen wholly owned subsidiary company company regarding propulsid state federal courts across country approximately cases currently pending including claims approximately plaintiffs active cases individuals alleged died use propulsid actions seek substantial compensatory punitive damages accuse janssen company inadequately testing warning drug 's side effects promoting offlabel use promotion addition janssen company entered agreements tolling agreements various plaintiffs ' counsel halting running statutes limitations respect potential claims significant number individuals attorneys evaluate whether sue janssen company behalf september first ten plaintiffs rankin case comprises claims propulsid plaintiffs went trial state court claiborne county mississippi jury returned compensatory damage verdicts plaintiff amount million total million trial judge thereafter dismissed claims punitive damages march trial judge reduced verdicts total million denied motions janssen company new trial may supreme court mississippi reversed verdicts janssen company remanded case trial court supreme court found joint trial multiple plaintiffs ' cases janssen prejudicial directed trial court return cases individual plaintiffs separate trials home counties motion rehearing denied onaugust april state court judge new jersey denied plaintiffs ' motion certify national class propulsid users purposes medical monitoring refund costs purchasing propulsid effort appeal ruling denied june federal judge presiding propulsid multidistrict litigation new orleans louisiana similarly denied plaintiffs ' motion certify national class propulsid users plaintiffs multidistrict litigation said preserving right appeal ruling complaints filed janssen company include class action allegations could basis future attempts classes certified february janssen announced reached agreement principle plaintiffs steering committee psc propulsid federal multidistrict litigation mdl resolve federal lawsuits related propulsid approximately individuals included federal mdl approximately alleged died use drug agreement becomes effective percent death claims percent remainder agree terms settlement addition individuals filed lawsuits whose claims subject tolling agreements suspending running statutes limitations claims must also agree participate settlement become effective agreeing participate settlement submit medical records independent panel physicians determine whether claimed injuries caused propulsid otherwise meet standards compensation standards met courtappointed special master determine compensatory damages agreement becomes effective janssen pay compensation minimum million maximum million depending upon number plaintiffs enroll program janssen also establish administrative fund exceed million pay legal fees psc million subject court approval respect various propulsid actions janssen company dispute claims lawsuits vigorously defending except judgment settlement appropriate janssen company believe adequate selfinsurance accruals third party product liability insurance respect cases communications company excess insurance carriers raised certain defenses liability policies date declined reimburse janssen company propulsidrelated costs despite demand payment however opinion company defenses pro forma lack substance carriers honor obligations policies either voluntarily litigation march company commenced arbitration allianz underwriters insurance company issued first layer applicable excess insurance coverage obtain reimbursement propulsidrelated costs arbitration currently scheduled begin mid may last several weeks company 's ethicon inc subsidiary last several years number claims lawsuits filed relating vicryl sutures actions allege sterility vicryl sutures compromised inadequacies ethicon 's systems controls causing patients exposed sutures incur infections would otherwise occurred ethicon several occasions recalled batches vicryl sutures light questions raised sterility believe contamination suture products fact occurred november trial judge west virginia certified class treatment west virginia residents vicryl sutures implanted class ii surgeries may december certification subject later challenge following conclusion discovery previous trial date adjourned reset ethicon intends continue vigorously defending claims affirmative stent patent litigation patent infringement actions tried delaware federal court late cordis corporation subsidiary johnson johnson obtained verdicts infringement patent validity damage awards boston scientific corporation medtronic ave inc based number cordis vascular stent patents december jury damage action boston scientific returned verdict million december jury medtronic ave action returned verdict million sums represent lost profit reasonable royalty damages compensate cordis infringement include pre post judgment interest february hearing held claims boston scientific medtronic ave patents issue unenforceable owing alleged inequitable conduct beforethe patent office march may district judge issued post trial rulings confirmed validity enforceability main cordis stent patent claims found certain cordis patents unenforceable district judge granted boston scientific new trial liability damages vacated verdict medtronic ave legal grounds august court appeals federal circuit found trial judge erred vacating verdict medtronic ave remanded case trial judge proceedings trial judge scheduled trial march boston scientific medtronic ave connection cordis ' efforts obtain reinstatement original verdicts january cordis filed additional patent infringement action boston scientific delaware federal court accusing express taxus stents infringing one cordis patents involved earlier actions boston scientific medtronic ave february cordis moved action preliminary injunction seeking bar introduction taxus stent based patent november district judge denied request preliminary injunction decision affirmed court appeals federal circuit may trial case scheduled june cordis also pending delaware federal court another action medtronic ave accusing medtronic ave infringement sale stent products introduced medtronic ave subsequent gfx microstent products subject earlier action referenced early june arbitration panel chicago preliminary ruling found favor cordis arbitration acsguidant involving infringement acsguidant cordis stent patent august panel confirmed ruling rejecting challenge acsguidant terms earlier agreement cordis acsguidant arbitration panel 's ruling obligated acsguidant make payment million cordis made fiscal fourth quarter result resolving matter fiscal fourth quarter million recorded income expense approximately million tax relating past periods balance award million approximately million tax recognized income future periods estimated remaining life intellectual property commencing first fiscal quarter additional royalties acsguidant 's continued use technology injunction involved patent litigation various johnson johnson operating companies products various johnson johnson operating companies subject various patent lawsuits could potentially affect ability operating companies sell products require payment past damages future royalties following chart summarizes various patent lawsuits concerning important products johnson johnson operating companies respect matters johnson johnson operating company involved vigorously defending claims infringement disputing appropriate validity enforceability patent claims asserted table caption jj plaintiff oper patent trial date product company patents holder court date filed c c c c c c stents cordis jang boston ddel scientific corporation drug cordis ding boston ddel eluting scientific stents corporation drug cordis kunz boston ddel eluting grainger scientific stents corporation stents cordis rockey arlaine sdfla tbd gena rockey inc stents cordis boneau medtronic ddel tbd inctwo cordis kastenho boston ndcal tbd layer fer scientific cathet forman corporation ers remi centocor cerami rockefeller edtex cade university chiron corporation two cordis kastenho boston belgium layer fer scientific cathet corporation ers schneider stents cordis israel medinol multiple st eu trial juris nether dictions lands contact vision nicolson ciba md fla lenses care vision table litigation filers abbreviated new drug applications andas following chart indicates lawsuits pending generic firms filed abbreviated new drug applications seeking market generic forms products sold various subsidiaries company prior expiration applicable patents covering products andas typically include allegations noninfringement invalidity unenforceability patents event subsidiary company involved successful actions firms involved introduce generic versions product issue resulting substantial market share revenue losses product company 's subsidiary table caption brand name patentnda generic court trial date product holder challenger date filed c c c c c aciphex eisai teva sdny tbd mg delay dr sdny tbd release janssen reddy 's sdny tbd tablet mylan ditropan xl ortho mylan dwv mg mcneil impax ndcal tbd controlled alza release tablet duragesic janssen mylan vt alza microgramshr patch levaquin daiichi mylan dwv tablets jjprd orthomcneil teva dnj tbd mg tablets levaquin injectable daiichi bedford dnj tbd single use jjprd ben vials ortho venue mlmg mcneil sicor dnj tbd premix teva levaquin daiichi american dnj tbd injectable jjprd pharmac single use ortho eutical vials mcneil partners quixin daiichi hitech dnj tbd ophthalmic ortho pharmacalsolution mcneil levo floxacin ophthalmic solution ortho tri ortho barr dnj tbd cyclen lo mcneil mg mg mg mg mg mg risperdal janssen mylan dnj tbd tablets dr dnj tbd reddy 's mg tablets sporanox janssen eon labs edny mg capsule topamax ortho mylan dnj tbd mcneil mg tablet ultracet ortho kalipar dnj tbd tram mcneil teva dnj tbd apap caraco ed tbd tablet mich pepcid mcneil perrigo sdny tbd complete ppc inc table duragesic fentanyl transdermal system matter referenced district court march found alza 's patent valid enforceable infringed mylan 's generic decision affirmed court appeals federal court june fda ruled mylan 's anda would subject alza 's period pediatric exclusivity ending january late june mylan filed actions fda seeking require agency grant approval market july day duragesic patent expired august district court ruled mylan favor fda 's recognition pediatric exclusivity duragesic decision affirmed court appeals district columbia circuit action mylan involving levaquin trial judge december found patent issue valid enforceable infringed mylan 's contemplated anda product issued injunction precluding sale product patent expiration late mylan appealed court appeals federal circuit action eon labs involving sporanox itraconazole district court ruled july janssen 's patent valid infringed eon 's generic janssen appealed ruling court appeals federal circuit eon launched generic version sporanox february action kali involving ultracet tramadol hydrochloride acetaminophen kali moved summary judgment issues infringement invalidity briefing motion completed october decision expected anytime respect claims issue litigation kali orthomcneil filed reissue application us patent trademark office seeking narrow scope claims action mylan involving ditropan xl oxybutynin chloride mylan moved summary judgment july issues noninfringement invalidity motion denied december action mylan relating topamax topiramate mylan october filed motion summary judgment noninfringement orthomcneil 's patent decision expected february respect matters johnson johnson operatingcompany involved vigorously defending validity enforceability asserting infringement licensor 's patents average wholesale price awp litigation johnson johnson pharmaceutical operating companies along numerous pharmaceutical companies defendants series lawsuits state federal courts involving allegations pricing marketing certain pharmaceutical products amounted fraudulent otherwise actionable conduct among things companies allegedly reported inflated average wholesale price drugs issue cases federal actions state actions removed federal court consolidated pretrial purposes multidistrict litigation mdl federal court boston massachusetts plaintiffs cases include classes private persons entities paid portion purchase drugs issue based awp state government entities made medicaid payments drugs issue based awp mdl proceeding boston plaintiffs moved class certification portion claims decision expected motion second third quarter ethicon endosurgery inc johnson johnson operating company markets endoscopic surgical instruments company named defendants north carolina state court class action lawsuit alleging awp inflation improper marketing activities tap pharmaceuticals ethicon endosurgery inc defendant based claims several former sales representatives alleged involved arbitrage tap drug allegation sales representatives persuaded certain physicians states drug 's price low purchase tap excess quantities drug resell states price higher ethicon endosurgery inc company deny liability claims made case vigorously defending april trial judge certified national class purchasers tap product issue july class decertified north carolina court appeals matter remanded trial court additional consideration january trial judge certified north carolina state class purchases tap product question trial date set matter new york state attorney general 's office federal trade commission issued subpoenas january february seeking documents relating marketing sutures endoscopic instruments company 's ethicon inc ethicon endosurgery inc subsidiaries connecticut attorney general 's office also issued subpoena documents subpoenas focus bundling sutures endoscopic instruments contracts offered group purchasing organizations individual hospitals discounts predicated hospital achieving specified market share targets categories products operating companies involved responded subpoenas june company received request records information us house representatives ' committee energy commerce connection investigation pharmaceutical reimbursements rebates medicaid committee 's request focuses drug remicade infliximab marketed company 's centocor inc subsidiary july centocor received request voluntarily provide documents information criminal division us attorney 's office district new jersey connection investigation various centocor marketing practices company centocor responded requests documents information august securities exchange commission sec advised company informal investigation foreign corrupt practices act allegations payments polish governmental officials us pharmaceutical companies november sec advised company investigation become formal issued subpoena information previously requested informal fashion plus background documents company operating units poland responded requests december company 's orthomcneil pharmaceutical unit received subpoena united states attorney 's office boston massachusetts seeking documents relating marketing including alleged offlabel marketing drug topamax topiramate orthomcneil cooperating responding subpoena october us attorney 's office boston asked attorneys orthomcneil pharmaceutical cooperate facilitating subpoenaed testimony several present former orthomcneil witnesses grand jury boston cooperation providedon january company 's janssen unit received subpoena office inspector general united states office personnel management seeking documents concerning sales marketing payments physicians connection sales marketing clinical trials risperdal risperidone documents subsequent also requested janssen cooperating responding subpoena april company 's pharmaceutical units requested submit information senate finance committee use nominal pricing exception calculating best price medicaid rebate program request sent manufacturers top twenty drugs reimbursed medicaid program company 's pharmaceutical units responded request july company received letter request new york state attorney general 's office documents pertaining marketing offlabel sales clinical trials topamax topiramate risperdal risperidone procrit epoetin alfa reminyl galantamine hbr remicade infliximab aciphex rabeprazole sodium company responding request august johnson johnson health care systems inc johnson johnson operating company received subpoena dallas texas u attorney 's office seeking documents relating relationships group purchasing organization novation hcs johnson johnson operating companies company 's operating entities involved responding subpoena september ortho biotech inc received subpoena us office inspector general 's denver colorado field office seeking documents directed sales marketing procrit epoetin alfa present ortho biotech responding subpoena september plaintiffs employment discrimination litigation initiated company moved certify class african american hispanic salaried employees company affiliates united states employed time november present plaintiffs seek monetary damages period present including punitive damages equitable relief company expected file response plaintiffs ' class certification motion first half decision district court expected late company disputes allegations lawsuit vigorously defending remand federal circuit court appeals january partial retrial commenced october concluded november boston massachusetts action amgen v transkaryotic therapies inc tkt aventis pharmaceutical inc matter patent infringement action brought amgen tkt developer geneactivated epo product aventis holds marketing rights tkt product asserting tkt 's product infringes various amgen patent claims tkt aventis dispute infringement seeking invalidate amgen patents asserted october district court issued rulings upheld initial findings amgen 's patent claims valid infringed proceedings appeal follow amgen patents issue case exclusively licensed ortho biotech inc johnson johnson operating company us nondialysis indications ortho biotech inc party action october companion action brought tkt aventis amgen ortho biotech 's uk affiliate united kingdom house lords acting highest court uk invalidated pertinent claims amgen 's uk patent epo expired december company also involved number patent trademark lawsuits incidental business ultimate legal financial liability company respect claims lawsuits proceedings referred estimated certainty however opinion management based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities already accrued company 's balance sheet expected material adverse effect company 's financial position although resolution reporting period one matters could significant impact company 's results operations cash flows period earnings per sharethe following reconciliation basic net earnings per share diluted net earnings per share years ended january december december table caption shares millions c c c basic earnings per share average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares adjusted average shares outstanding diluted diluted earnings per share table diluted earnings per share calculation includes dilution effect convertible debt decrease interest expense million million million tax years respectively diluted earnings per share excludes million million million shares underlying stock options respectively exercise price options greater average market value resulting antidilutive effect diluted earnings per share capital treasury stock changes treasury stock table caption amounts millions except treasury stock number shares thousands shares amount c c balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock balance january table shares common stock issued shares end cash dividends paid per share compared dividends per share per share selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized table caption dollars millions first second third fourthexcept per share data qtr qtr qtr qtr c c c c segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share table table caption dollars millions first second third fourth except per share data qtr qtr qtr qtr c c c c segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share table third quarter includes aftertax charge million inprocess research development iprd costs fourth quarter includes million taxes repatriation unremitted foreign earnings associated american jobs creation act first quarter includes aftertax charge million iprd costs second quarter includes aftertax charge million iprd costs fourth quarter includes aftertax income million arbitration ruling stent patents cost retirement enhancement program million management 's report internal control financial reporting section sarbanesoxley act management required assess effectiveness company 's internal control financial reporting end fiscal year report based assessment whether company 's internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting company 's internal control financial reporting designed provide reasonable assurance reliability company 's financial reporting preparation offinancial statements external purposes accordance generally accepted accounting principles internal control financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate company 's management assessed effectiveness company 's internal control financial reporting january making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring company 's assessment included extensive documenting evaluating testing design operating effectiveness internal control financial reporting based company 's processes assessment described management concluded january company 's internal control financial reporting effective management 's assessment effectiveness company 's internal control financial reporting january audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein report independent registered public accounting firm shareholders board directors johnson johnson completed integrated audit johnson johnson 's fiscal consolidated financial statements internal control financial reporting january audits fiscal fiscal consolidated financial statements accordance standards public company accounting oversight board united states opinions based audits presented consolidated financial statements opinion accompanying consolidated balance sheets related consolidated statements earnings statements equity statements cash flows present fairly material respects financial position johnson johnson subsidiaries company january december results operations cash flows three years period ended january conformity accounting principles generally accepted united states america financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits statements accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit financial statements includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion internal control financial reporting also opinion management 's assessment management 's report internal control financial reporting appearing annual report shareholders company maintained effective internal control financial reporting january based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso fairly stated material respects based criteria furthermore opinion company maintained material respects effective internal control financial reporting january based criteria established internal control integrated framework issued coso company 's management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinions onmanagement 's assessment effectiveness company 's internal control financial reporting based audit conducted audit internal control financial reporting accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit internal control financial reporting includes obtaining understanding internal control financial reporting evaluating management 's assessment testing evaluating design operating effectiveness internal control performing procedures consider necessary circumstances believe audit provides reasonable basis opinions company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp new york new york february segments business geographic areas johnson johnson subsidiaries table caption sales customers dollars millions c c c consumer united states international total pharmaceutical united states international total med devices diag united states international total worldwide total table table caption operating profit dollars millions c c c consumer pharmaceutical medical devices diagnostics segments total expenses allocated segments general corporate worldwide total table table caption identifiable assets dollars millions c c c consumer pharmaceutical medical devices diagnostics segments total expenses allocated segments general corporate worldwide total table table caption additions property plant equipment dollars millions c c c consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total table table caption depreciation amortization dollars millions c c c consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total table table caption sales customers dollars millions c c c united states europe western hemisphere excluding us asiapacific africa segments total worldwide total table table caption longlived assets dollars millions c c c united states europe western hemisphereexcluding us asiapacific africa segments total general corporate non longlived assets worldwide total table see management 's discussion analysis description segments company business export sales intersegment sales significant sales top three distributors accounted amounts allocated segments include interest incomeexpense minority interest general corporate income expense general corporate includes cash marketable securities includes million inprocess research development iprd medical devices diagnostics segment includes million iprd pharmaceutical segment million iprd million arbitration ruling stent patents medical devices diagnostics segment includes million iprd million million costs related arbitration settlement procrit pharmaceutical segment million iprd medical devices diagnostics segment longlived assets include property plant equipment net respectively intangible assets net respectively summary operations statistical data johnson johnson subsidiaries dollars millions except per share figures table caption c c c c c c sales customers us sales customers international total sales cost products sold selling marketing admin expenses research expense purchased inprocess research development interest income interest expense net portion capitalized income expense net earnings provision taxes income provision taxes income net earnings percent sales tocustomers diluted net earnings per share common stock percent return average shareholders ' equity percent increase previous year sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maint repairs total tax expense supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders ' equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands table table caption c c c c c sales customers us sales customers international total sales cost products sold selling marketing admin expenses research expense purchased inprocess research development interest income interest expense net portion capitalized income expense net earnings provision taxes income provision taxes income net earnings percent sales customers diluted net earnings pershare common stock percent return average shareholders ' equity percent increase previous year sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maint repairs total tax expense supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders ' equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands table net interest income also included cost materials services category includes taxes income payroll property business taxes text document document typeex sequence filenameyexvtxt descriptionsubsidiaries text exhibit subsidiaries johnson johnson new jersey corporation domestic international subsidiaries shown certain us subsidiaries international subsidiaries named significant aggregate johnson johnson parent table caption jurisdiction name subsidiary organization c us subsidiaries alza corporation delaware alza land management inc delaware biosense webster inc california centocor biologics llc pennsylvaniacentocor inc pennsylvania centocor research development inc pennsylvania codman shurtleff inc new jersey cordis corporation florida cordis development corporation florida cordis international corporation delaware cordis llc delaware cordis neurovascular inc florida crescendo pharmaceuticals corporation delaware depuy disc inc delaware depuy inc delaware depuy mitek inc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine inc ohio depuy spine sales limited partnership massachusetts diabetes diagnostics inc delaware egea biosciences llc delaware ethicon endosurgery inc ohio ethicon endosurgery llc new mexico ethicon endosurgery services lp texas ethicon inc new jersey ethicon llc delaware global biologics supply chain llc pennsylvania gynopharma inc delaware iso merger corp delaware janssen finance company florida janssen inc delaware janssen ortho llc delaware janssen pharmaceutica inc pennsylvania janssen pharmaceutica products lp new jersey jjhc llc delaware johnson johnson baby products inc delaware johnson johnson consumer companies inc new jersey johnson johnson development corporation new jersey table table caption jurisdiction name subsidiary organization c johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson merck consumer pharmaceuticals co new jersey johnson johnson middle east inc new jersey johnson johnson pharmaceutical research development llc new jersey johnson johnson professional co pr inc delaware johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida joint medical products corporation delaware lifescan inc california lifescan llc delaware mcneil nutritionals llc delaware mcneilppc inc new jersey middlesex assurance company limited vermont neutrogena corporation delaware nitinol development corporation california noramco inc georgia omj pharmaceuticals inc delaware orapharma inc delaware ortho biologics llc delaware ortho biotech holding corp delaware ortho biotech inc new jersey ortho biotech products lp new jersey orthoclinical diagnostics inc new york orthomcneil finance co florida orthomcneil pharmaceutical inc delaware rutan realty llc new jersey scios inc delaware sweetfranchise inc delaware teramed corporation delaware therakos inc florida therapeutic discovery corporation delaware tylenol company new jerseywinthorpe valentine inc delaware international subsidiaries alza ireland limited ireland apsis sas france biapharm sas france centocor biologics ireland limited ireland centocor bv netherlands cilag advanced technologies gmbh switzerland cilag ag switzerland cilag ag international switzerland cilag holding ag switzerland table table caption jurisdiction name subsidiary organization c codman sarl switzerland cordis europa nv netherlands cordis medizinische apparate gmbh germany cordis sas france depuy ace sarl switzerland depuy australia pty ltd australia depuy france sas france depuy international limited united kingdom depuy intl holdings limited united kingdom depuy ireland limited ireland depuy mitek sarl switzerland depuy orthopadie gmbh germany depuy orthopedie sas france depuy spine sarl switzerland depuy uk holdings limited united kingdom ethicon gmbh germany ethicon ireland limited ireland ethicon sarl scotland ethicon sas france ethnor proprietary limited south africa greiter ag switzerland greiter international ag switzerland janssen animal health bvba belgium janssencilag norway janssencilag ab sweden janssencilag ag switzerland janssencilag bv netherlands janssencilag farmaceutica lda portugal janssencilag farmaceutica ltda brazil janssencilag gmbh germany janssencilag ltd united kingdom janssencilag nv belgium janssencilag pharmaceutical saci greece janssencilag pharma gmbh austria janssencilag polska sp z oo poland janssencilag pty ltd australia janssencilag sa spain janssencilag sa de cv mexico janssencilag sas france janssencilag spa italy janssen korea ltd korea janssen pharmaceutica nv belgium janssen pharmaceutica pty limited south africa janssen pharmaceutical kk japan janssen pharmaceutical limited ireland jc general services cvba belgium jc healthcare ltd israel table table caption jurisdiction name subsidiary organization c jhc nederland bv netherlands johnson johnson ab sweden johnson johnson ag switzerland johnson johnson china investment co ltd china johnson johnson china ltd chinajohnson johnson comercio e distribuicao ltda brazil johnson johnson consumer france sas france johnson johnson de argentina sace argentina johnson johnson de colombia sa colombia johnson johnson de venezuela sa venezuela johnson johnson european treasury company ireland johnson johnson egypt sae egypt johnson johnson finance limited england johnson johnson gesellschaft mbh austria johnson johnson gmbh germany johnson johnson group holdings gmbh germany johnson johnson hellas sa greece johnson johnson holding ab sweden johnson johnson holding gmbh germany johnson johnson hong kong limited hong kong johnson johnson inc canada johnson johnson international financial services company ireland johnson johnson international sa france johnson johnson ireland limited ireland johnson johnson kft hungary johnson johnson kk japan johnson johnson korea ltd korea johnson johnson limitada portugal johnson johnson limited india johnson johnson management limited england johnson johnson medical bv netherlands johnson johnson medical china ltd china johnson johnson medical holding spa italy johnson johnson medical korea limited korea johnson johnson medical limited scotland johnson johnson medical mexico sa de cv mexico johnson johnson medical products gmbh austria johnson johnson medical pty limited south africa johnson johnson medical pty limited australia johnson johnson medical sa argentina johnson johnson medical spa italy johnson johnson morocco sa morocco johnson johnson pacific pty limited australia johnson johnson pakistan private limited pakistan johnson johnson philippines inc philippines johnson johnson poland sp z oo poland johnson johnson produtos profissionais ltda brazil table table caption jurisdiction name subsidiary organization c johnson johnson proprietary limited south africa johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson research pty ltd australia johnson johnson sa spain johnson johnson sa de cv mexico johnson johnson sdn bhd malaysia johnson johnson spa italy johnson johnson sro czech republic johnson johnson swiss finance company limited united kingdom johnson johnson taiwan ltd taiwan johnson johnson thailand ltd thailand johnson johnson vision care ireland limited ireland kk depuy japan japan laboratoires polive snc france lifescan canada ltd canada lifescan scotland ltd scotland mcneil gmbh co arzneimittelvertrieb ohg germany mcneil gmbh co ohg germany mcneil iberica slu spain mcneil pdi inc canada mcneil sas france medos international sarl switzerland medos sarl switzerland omj ireland limited ireland omj manufacturing limited ireland orthoclinical diagnostics united kingdom orthoclinical diagnostics gmbh germany orthoclinical diagnostics kk japanorthoclinical diagnostics sa france pt johnson johnson indonesia indonesia shanghai johnson johnson pharmaceuticals ltd china tasmanian alkaloids pty ltd australia tibotec bvba belgium tibotec pharmaceuticals ltd ireland tibotecvirco comm va belgium vania expansion snc france virco bvba belgium xianjanssen pharmaceutical ltd china table text document document typeex sequence filenameyexvtxt descriptionconsent independent registered public accounting firm text exhibit consent independent registered public accounting firm hereby consent incorporation reference registration statements form file form file johnson johnson report dated february relating financial statements management 's assessment effectiveness internal control financial reporting effectiveness internal control financial reporting appears annual report shareholders incorporated annual report also consent incorporation reference report dated march relating financial statement schedule appears form k pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york march text document document typeexa sequence filenameyexvwatxt descriptioncertification text exhibit certification chief executive officer pursuant section sarbanesoxley act william c weldon certify reviewed annual report johnson johnson company based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows company periods presented report company 's certifying officer responsible establishing maintaining disclosure controls procedures defined exchange act rules ae internal control financial reporting defined exchange act rules af company havea designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness company 's disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change company 's internal control financial reporting occurred company 's fourth fiscal quarter materially affected reasonably likely materially affect company 's internal control financial reporting company 's certifying officer disclosed based recent evaluation internal control financial reporting company 's auditors audit committee company 's board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect company 's ability record process summarize report financial information b fraud whether material involves management employees significant role company 's internal control financial reporting william c weldon william c weldon chief executive officer date march text document document typeexb sequence filenameyexvwbtxt descriptioncertification text exhibit b certification chief financial officer pursuant section sarbanesoxley act robert j darretta certify reviewed annual report johnson johnson company based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows company periods presented report company 's certifying officer responsible establishing maintaining disclosure controls procedures defined exchange act rule ae internal control financial reporting defined exchange act rules af company andhave designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness company 's disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change company 's internal control financial reporting occurred company 's fourth fiscal quarter materially affected reasonably likely materially affect company 's internal control financial reporting company 's certifying officer disclosed based recent evaluation internal control financial reporting company 's auditors audit committee company 's board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect company 's ability record process summarize report financial information b fraud whether material involves management employees significant role company 's internal control financial reporting robert j darretta robert j darretta chief financial officer date march text document document typeexa sequence filenameyexvwatxt descriptioncertification text exhibit certification chief executive officer pursuant section sarbanesoxley act undersigned william c weldon chief executive officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies company 's annual report fiscal year ended january report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company william c weldon william c weldon chief executive officer dated march certification furnished sec report form k pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act text document document typeexb sequence filenameyexvwbtxt descriptioncertification text exhibit b certification chief financial officer pursuant section sarbanesoxley act undersigned robert j darretta chief financial officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies company 's annual report fiscal year ended january report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company robert j darretta robert j darretta chief financial officer dated march certification furnished sec report form k pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act text document document typeexb sequence filenameyexvwbtxt descriptioncautionary statement pursuant private securities text exhibit b cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements company may time time make certain forwardlooking statements publiclyreleased materials written oral forwardlooking statements relate strictly historical current facts anticipate results based management 's plans subject uncertainty forwardlooking statements may identified use words like plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance company 's strategy growth product development regulatory approvals market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially company 's expectations projections investors therefore cautioned place undue reliance forwardlooking statements furthermore company assumes obligation update forwardlooking statements result new information future events developments important factors could cause company 's actual results todiffer company 's expectations forwardlooking statements follows economic factors including inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins competitive factors including technological advances achieved patents attained competitors well new products introduced competitors including fact continued competition us procrit topselling product company 's portfolio within last year competition cypher drugeluting stent challenges company 's patents competitors allegations company 's products infringe patents third parties could potentially affect company 's competitive position ability sell products question require payment past damages future royalties particular generic drug firms filed abbreviated new drug applications seeking market generic forms company 's key pharmaceutical products prior expiration applicable patents covering products event company successful defending resulting lawsuits generic versions product issue introduced resulting substantial market share revenue losses financial distress bankruptcies experienced significant customers suppliers could impair ability case may purchase company 's products pay products previously purchased meet obligations company supply arrangements impact political economic conditions due terrorist attacks us parts world us military action overseas well instability financial markets could result terrorism military actions interruptions computer communication systems including computer viruses could impair company 's ability conduct business communicate internally customers health care changes us countries resulting pricing pressures including continued consolidation among health care providers trends toward managed care health care cost containment government laws regulations relating sales promotion reimbursement pricing generally government laws regulations affecting us foreign operations including relating securities laws compliance trade monetary fiscal policies taxes price controls regulatory approval new products licensing patent rights including particular proposed amendments hatchwaxman act implementation recently enacted medicare prescription drug improvement modernization act possible drug reimportation legislation competition research involving development improvement new existing products processes particularly significant results time time product process obsolescence development new improved products important company 's success areas business difficulties inherent product development including potential inability successfully continue technological innovation complete clinical trials obtain regulatory approvals united states abroad gain maintain market approval products possibility encountering infringement claims competitors respect patent intellectual property rights preclude delay commercialization product significant litigation adverse company including product liability claims patent infringement claims antitrust claims health care industry come increased scrutiny government agencies state attorney generals resulting investigations prosecutions carry risk significant civil criminal penalties including debarment government business product efficacy safety concerns resulting product recalls regulatory action part fda foreign counterparts declining sales company 's affiliates sell coxinhibitor medicines recent developments involving medicines demonstrate risks likely implications throughout health care industry impact business combinations including acquisitions divestitures internally company externally pharmaceutical health care industries issuance new revised accounting standards american institute certified public accountants financial accounting standards board securities exchange commission public company accounting oversight board foregoing list sets forth many factors could impact upon company 's ability achieve results described forwardlooking statements investors understand possible predict identify factors consider list complete statement potential risks uncertainties company identified factors list permitted private securities litigation reform act text document secdocument end privacyenhanced message